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Neonatal hypoxia ischemia (HI) is an injury caused to the immature brain due to 
reduced cerebral blood flow which is associated with life-long neurological impairments. 
HI causes oxidative protein folding in the endoplasmic reticulum (ER), which results in 
ER stress. Generation of reactive oxygen species (ROS), from cytochrome P450 
members (CYP) and NADPH-P450 reductases (NPR), in combination with activation of 
the unfolded protein response (UPR) are two major consequences of ER stress that cause 
oxidative damage and cell death.  
Herein we identified the role of Bax Inhibitor-1 (BI-1), an evolutionary conserved 
protein encoded by the Transmembrane Bax inhibitor Motif Containing 6 (TMBIM6) 
gene, in protection from ER stress after HI injury in the neonatal rat. As BI-1 has 
multimodal properties that can target a wide array of pathophysiological consequences 
after injury, our main objective was to evaluate BI-1’s protective mechanisms by 
overexpressing it, using viral-mediated gene delivery of human adenoviral-TMBIM6 
(Ad-TMBIM6) vector, in an in vitro and in vivo model of HI.  
Following the Rice-Vannuci model, ten-day old (P10) rat pups underwent right-
unilateral carotid artery ligation followed by 1.5h of hypoxia. Our results showed that 
overexpression of BI-1 ameliorated short and long-term deficits following HI.  There was 
 xiv 
a significant reduction in percent infarcted area which was linked with attenuation of 
apoptosis, reduction of ROS accumulation and inhibition of pro-inflammatory mediators. 
BI-1 mediated protection was observed to be via both inhibition of IRE1α signaling, a 
stress sensor protein part of the UPR response, and P4502E1 activity, a major contributor 
of ROS generation. Attenuation of apoptosis was associated with a decrease in IRE1α-
XBP1 levels while decreased levels of P4502E1 coupled with upregulation of Nrf-2 and 
HO-1, anti-oxidant enzymes, were correlated with a reduction in ROS generation and 
inflammation.  
In conclusion we established that overexpression of BI-1 attenuated the 
morphological and neurological consequences post HI via inhibition of ER stress induced 
pathways. This new finding may help to provide a basis for BI-1 as a potential 
therapeutic target.   
 
 
 1 
CHAPTER ONE 
INTRODUCTION 
Neonatal Hypoxia Ischemia 
Neonatal Hypoxic-ischemic (HI) brain injury, caused by asphyxia, remains the 
leading cause of neonatal morbidity and mortality (Volpe 1976). The predominant 
pathogenic mechanisms of asphyxia are, hypoxemia, which is reduced amount of oxygen 
in the blood supply, or reduced cerebral blood flow (ischemia), which is a diminished 
amount of blood perfusing the brain. The term asphyxia is clinically used to describe an 
impairment in placental or pulmonary gas exchange before, during or soon after birth and 
is diagnosed as hypoxic ischemic encephalopathy (HIE) (Volpe 2001).  
Impaired gas exchange may be from the fetus, the mother or uteroplacental 
disruption. Fetal causes may result from umbilical cord complications, fetomaternal 
hemorrhage and cardiac arrhythmia. Maternal causes may result from cardiac arrest, 
hypovolemic shock, asphyxiation, status epilepticus or severe anaphylactoid reaction. 
Uteroplacental causes are due to placental abruption or infection, cod prolapse, uterine 
rupture or hyperstimulation (Rootwelt et al. , 1995). Generally, the newborn can 
compensate for brief periods of depleted oxygen, however, if the asphyxia lasts too long 
brain tissue is destroyed. These adverse events that occur to the newborn immature brain 
often lead to severe impairments such as pulmonary immaturity, respiratory distress 
syndrome, hypercapnia, hypo perfusion, mental retardation, epilepsy, cerebral palsy, 
seizures and long-term cognitive and behavioral deficits. 
HIE is increasingly becoming burdensome not only for the patients and their 
families but also for the US healthcare with lifelong costs projected for cerebral palsy 
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alone at $11.5 billion (Wirrell et al. , 2001; Bracewell et al. , 2002; Ferriero 2004; Bartha 
et al. , 2007; Derrick et al. , 2007). Therefore, it is imperative to investigate and 
understand HIE pathophysiology and signaling pathways to help us establish successful 
treatment strategies for the management of these patients.  
 
Epidemiology 
HIE is a major burden of disease to not only patients but also their families with 
more than a million children who survive birth asphyxia develop long-term complications 
such as cerebral palsy, mental retardation and cognitive and behavioral deficits (Ferriero 
2004; Zanelli et al. , 2011). The prevalence of HIE in developing countries is reported to 
be 10 times higher compared to technologically advanced countries. In the United states 
alone, the incidence is 1-4 cases per 1000 births. According to the World Health 
Organization, 23% of neonates worldwide have birth asphyxia (920,000 neonatal deaths) 
while causing another 1.1 million intrapartum stillbirths (Volpe 2001; Cerio et al. , 2013). 
From the patients that experience moderate to severe HIE, mortality rates are reported at 
23-50% prior to discharge, and between 37-38% at a 18-22month follow up (Gluckman 
et al. , 2005; Shankaran et al. , 2005). Moreover, 80% of the cases that experience severe 
encephalopathy develop serious long-term complications and approximately 30-50% of 
those that survive with moderate to severe injury will develop long-term complications 
(Vannucci et al. , 1999; Zanelli et al. , 2011). Some cases in newborn infants that do not 
present neurological deficits at the initial period, may later develop long-term functional 
impairments. In a clinical study of children 7+ years old that had a history of moderately 
 3 
severe HIE, 15-20% of them developed learning difficulties, despite no obvious signs of 
brain injury (Robertson et al. , 2006; van Handel et al. , 2007). 
 
Pathophysiology  
Injury to the neonatal brain as a result of reduced cerebral blood flow and oxygen 
supply are the primary biological processes that lead to hypoxic-ischemic encephalopathy 
(HIE) (Grow et al. , 2002; Ferriero 2004; Perlman 2004). The amount of damage that the 
newborn sustains depends on the duration of insult, the age and apoptosis rate (Zanelli et 
al. , 2011).  
In the initial stages of depleted oxygen and blood supply to the brain, the neonate 
compensates for it by increasing cerebral blood flow (CBF) and redistributing the blood 
to the vital organs such as the brain, heart and adrenal glands. However, once this initial 
compensatory mechanism fails, CBF falls, blood pressure falls, and brain injury occurs. 
This leads to intracellular energy failure (Vannucci et al. , 2005; Hagberg et al. , 2016).  
In the primary energy failure stage, which occurs minutes after the insult, the 
sodium potassium ATP pump will begin to fail which will result in accumulation of 
sodium and calcium ions. This will induce neuronal depolarization and release of 
excitatory amino acids, such as glutamate, that can trigger further pathological cascade 
activation. Accumulation of calcium will recruit several enzymes, phospholipases, 
endonucleases and proteases, which results in cytoskeletal and DNA damage. At this 
stage apoptotic and necrotic cascades are activated which will cause cells to die (Hagberg 
et al. , 2016).       
Just before secondary energy failure occurs, there is an increase in free radical 
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production and calcium overload which causes oxidative stress, excitotoxicity, 
inflammation and apoptosis. The neonatal brain is highly susceptible to oxidative stress 
due to the low concentrations of antioxidants present and high consumption of oxygen. 
Cells will then begin to release pro-inflammatory cytokines which initiates an 
inflammatory response (Ferriero 2004). The second energy failure occurs 24-48h after 
injury and is characterized by mitochondrial dysfunction which leads to the ‘delayed 
phase of neuronal injury’ (Fatemi et al. , 2009; Lai et al. , 2011; Hagberg et al. , 2016), 
which is correlated with adverse neurodevelopmental outcomes. 
This window between primary and secondary energy failure is critical, as it is the 
optimal time for intervention strategies to ameliorate cell death. As apoptosis and 
necrosis progress at a high rate, it is crucial to rescue cells within hours of the insult 
otherwise the damage will become irreversible.  
 
Apoptotic Mechanisms  
Programmed cell death was first introduced in 1964 by Lockshin and colleagues. 
They suggested that the cell death occurring during development may not be a 
spontaneous or accidental event but instead, an intricate sequence of controlled processes 
leading to self-destruction (Lockshin et al. , 1965). The term apoptosis was then first 
brought in 1972 by Kerr and colleagues, where they used to describe the morphological 
processes leading to self-destruction (Kerr et al. , 1972). Apoptosis is an important 
process during development and is involved in differentiation, 
proliferation/homoeostasis, regulation and function of the immune system as well as 
removal of harmful cells (Fadel et al. , 1999).  
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The morphological features of an apoptotic cell are shrinkage of the cell, 
chromatin condensation, blebbing and finally fragmentation into small structures called, 
‘apoptotic bodies’. Necrosis, on the other hand, results in the cell bursting and releasing 
its contents into the cells’ environment thus inducing a strong inflammatory response 
(Leist et al. , 2001). Apoptosis is more prominent in less severe insults and is a delayed 
event associated with activation of caspase cascades, thus being a potential therapeutic 
target, whereas necrosis is more prevalent in severe HIE (Bonfoco et al. , 1995). In 2009, 
Fatemi and colleagues (Fatemi et al. , 2009) showed that activation of caspase 3 in a 
neonatal rodent model of HIE is prolonged and that it can persist for at least 7 days after 
the insult.  
Apoptotic pathways are intricate signaling mechanisms that have a variety of 
players. A cell can undergo apoptosis via two major pathways: the extrinsic or the 
intrinsic pathway. The extrinsic pathway, mainly mediated by death receptors, belongs to 
the tumor necrosis factor receptor (TNFR) gene family. These receptors are located on 
the cell surface and are triggered by their respective ligands to initiate apoptotic 
signaling. However, a signal coming from an activated receptor may not generate a 
strong enough signal to activate caspase cascades which are responsible for cell death. 
Therefore, this signal may be amplified via the mitochondrial-dependent apoptotic 
pathways by stimulating the pro-apoptotic Bcl-2 family members, Bax and Bak, which 
eventually result in caspase 3 activation leading to cell death (Fatemi et al. , 2009).   
The intrinsic signaling pathway mainly acts on the inside of the cell by disruption 
of mitochondrial membrane potential causing the release of pro-apoptotic mediators into 
the cytoplasm and is triggered by DNA damage and oxidative stress (Bernardi et al. , 
 6 
1999; Loeffler et al. , 2000; Wang et al. , 2001) which triggers the caspase cascade. In 
addition to the release of mitochondrial factors, cell homeostasis is disrupted which 
results in activation of redox molecules such as NADH, NADPH and accumulation of 
reactive oxygen species (ROS) triggering inflammatory responses. Although necrosis 
may prevail in severe HIE cases, apoptosis is a good target for therapeutics due to its 
delayed response and the potential target window that it presents.   
Many studies of animal models of HIE have shown that during the period after the 
injury many neurons die via activation of the pro-apoptotic protein, caspase-3. The 
expression of caspase 3 was shown to be very prolonged, which indicates a prolonged 
role of apoptosis after injury (Nakajima et al. , 2000). During this time, neurons can 
either die or survive over the next few days to weeks which gives ideal time for possible 
intervention strategies to preserve these neurons. Clinical studies that analyzed the 
cingulate gyrus of infants who either died from severe birth asphyxia with HIE or from 
sudden intrauterine death showed a significant number of apoptotic cells (Edwards et al. , 
1999). Caspases are proenzymes containing 3 subunits that cleave proteins in a specific 
way that represent the morphological features of an apoptotic cell (Banasiak et al. , 
2000). Caspase 3 is a widely studied caspase that plays a major role in neuronal death 
(Banasiak et al. , 2000).  In newborn piglets subjected to HIE, apoptotic cell death was 
detected morphologically and via DNA fragmentation 48h after the insult (Mehmet et al, 
1994). In a rat model, apoptotic cell injury began between 6-24h after HI (Chen et al. , 
2003). In addition, brains from postmortem infants that suffered HIE were examined and 
discovered high levels of caspase 3 (Rossiter et al. , 2002). Up to date, intervening at the 
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caspase level thus inhibiting caspase 3 has been the most common intervention following 
ischemia. 
 
Inflammatory Mechanisms  
Hypoxia ischemia triggers an inflammatory reaction that progresses for days to 
weeks and plays a role in secondary brain injury. Inflammation is complex process 
associated with the production and release of hundreds of signaling molecules such as 
cytokines, chemokines and ROS which are highly induced after ischemia in the neonatal 
brain (Szaflarski et al. , 1995; Hagberg et al. , 1996; Ivacko et al. , 1997; Barone et al. , 
1999; Cowell et al. , 2002). Cytokines have been implicated as important players in the 
pathogenesis of HIE and may represent a final common pathway of brain injury. This has 
been shown in animal studies, where levels of IL-1β were significantly upregulated after 
HI injury (Aly et al. , 2006; Liu et al. , 2013; Li et al. , 2014). However, details regarding 
the mechanisms or involvement of other cytokines in this process remains unclear. 
Additionally, there are several other factors that are induced after ischemia such as 
adhesion molecules (Frijns et al. , 2002), nitric oxide synthase (Forster et al. , 1999) and 
cyclooxygenase-1 (Nogawa et al. , 1997).  
Interleukins (ILs) such as TNFα, IL-6, IL-1β, IL-8 and tumor necrosis factors 
released after an HI insult are major pro-inflammatory cytokines that play a role in 
inflammatory processes and contribute to HI damage (Grow et al. , 2002). The 
inflammatory genes are evident as early as 8h after insult and further increased from 24 
to 72h post HI. Several studies have shown a correlation between injury and elevated 
levels of cytokine/inflammatory response. Patients with HIE have been shown to have 
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elevated levels of inflammatory cytokines and are associated with later development of 
cerebral palsy (Dammann et al. , 2008). Elevated levels of IL-6 and IL-8 have been 
observed in the CSF of newborns which were correlated with exacerbated HIE and poor 
neurodevelopmental outcome (Savman et al. , 1998). It has also been reported that HIE 
patients have a significantly higher expression of cytokine concentrations (Shalak et al. , 
2002). A cohort study of full term infants that experienced perinatal asphyxia revealed 
increased levels of IL-1β, IL-6 and TNFα when compared to normal infants (Foster-
Barber et al. , 2001). Those levels were observed in infants that either died at 1 year or 
went on to develop cerebral palsy. Another clinical study, using blood collected from the 
umbilical cord of infants that experienced asphyxia, revealed a 375-fold higher 
concentration of IL-6 in those patients that developed HIE. Thus, indicating that the 
immature brain is highly susceptible to the consequences of an inflammatory response 
(Anthony et al. , 1997; Bona et al. , 1999) making inflammation a prominent player in the 
pathogenesis of neonatal brain injury.  
In mice animal studies, that underwent unilateral carotid artery ligation, it was 
shown a significant increase in inflammatory genes in the injured hemisphere after the 
insult (Bona et al. , 1999). IL-1β and TNFα are early response cytokines that are 
synthesized and released by microglia, astrocytes and neurons.  Some of their features 
include the release of other cytokines, induction of leukocytes, influence of glial 
expression and stimulation of trophic factors (Szaflarski et al. , 1995). A study showed 
that when recombinant IL-1β receptor antagonist was administered it attenuated brain 
damage caused by HI in rats (Martin et al. , 1994; Hagberg et al. , 1996) which is an 
indicator that IL-1β plays a role in brain damage after HI. In 1995, Szaflarski and 
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colleagues demonstrated for the first time that ischemic insult stimulates cytokine 
production in the developing brain (Szaflarski et al. , 1995). In an HI rat model, IL-1β 
mRNA levels were significantly increased at 4h after HI. Furthermore, IL-1β triggers 
production of IL-6 which then acts together in response to HI. Another pro-inflammatory 
inhibitor, simvastatin was used as pretreatment for HIE and showed a reduction in 
expression of IL-1β and TNFα (Balduini et al. , 2004). Microglial activation, due to 
injury caused to the brain, secretes pro-inflammatory cytokines, extracellular proteases, 
and oxidative species, which damage surrounding tissue. This, in turn, stimulates a 
further release of pro-inflammatory mediators thus exacerbating the damage after HIE 
(Ivacko et al. , 1997; Yang et al. , 2015). Hence, targeting inflammatory response is 
critical to ameliorate HI induced injury. 
Several studies have achieved neuroprotection against ischemia by intervening 
with inflammatory mediator’s function.  For example, inhibition of either IL-1, TNFα or 
adhesion molecules conferred neuroprotection after ischemia (Relton et al. , 1992; 
Loddick et al. , 1996; Connolly et al. , 1997). Interleukins seem to play a major role in 
HIE progression as mice deficient in IL-18 or inhibition of IL-1 decreased CNS 
vulnerability to HI (Martin et al. , 1994; Hagberg et al. , 1996). Moreover, administration 
of the anti-inflammatory cytokine, IL-10 reduced HI insult (Mesples et al. , 2003).  
 
Oxidative Stress  
Before birth, the fetus is in a low oxygen environment however, in the first few 
minutes after birth, there is an abrupt increase in O2 levels (80-90%) creating pro-oxidant 
conditions to facilitate metabolic processes. In the event of pathological conditions, such 
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as after hypoxic ischemic (HI) insult, a serious of deleterious events occur such as excess 
calcium influx leading to oxidative stress (Allen et al. , 2011; Cao et al. , 2014; Zeeshan 
et al. , 2016). In animal models, it was reported to be a significant accumulation of H2O2 
in neonatal mice after HI but not in adult (Lafemina et al. , 2006). Decrease in oxygen in 
the newborn triggers a serious of events and the release of oxidases, NOS while 
simultaneously reducing anti-oxidant enzymes triggers a massive upregulation of ROS. A 
major target of ROS is the mitochondria, and the immature brain is especially susceptible 
to that because of its poor scavenging system. When the ROS exceeds the mitochondrial 
capacity, the resulting oxidative stress ruptures the mitochondrial membrane allowing the 
release of proteins with the potential to trigger inflammatory cascades that lead to 
apoptosis (Blomgren et al. , 2006; Nakai 2007). 
 
Clinical Presentation and Therapeutic Strategies 
Certain signs may appear shortly after birth such as organ dysfunction mainly the 
heart, lungs, kidneys and liver which is a good indicator of possible HIE. In severe cases, 
60% of the patients will develop seizures in the first 24h (Vasquez-Vivar et al. , 2017). 
Other evident symptoms include arched back, breathlessness, lethargy and some nausea 
and vomiting. Other symptoms that may be presented by the infant are difficulties 
suckling, eating, swallowing and excessive drooling.  In other cases, symptoms might not 
be evident at the time of birth but might become apparent later in life at the toddler ages.  
A child with birth injury may present symptoms later in life such as delay in motor skills, 
lack of muscle control, speech problems, learning difficulties and general loss of motor 
and learning abilities (Millar et al. , 2017).  
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Current treatment modalities for HIE include anticonvulsants, hypothermic treatments 
and fluid and electrolyte management, but despite the success of some of these, about 30-
50% of the patients will still develop serious long-term complications (Zanelli et al. , 
2011). The serious lack of understanding HI pathology, timing of therapeutic window and 
lack of mechanistic studies has made it crucial to investigate novel therapeutic 
approaches. It is imperative to understand the physiological cascades triggered by HI.  
 
Hypoxic Ischemic Injury and Endoplasmic Reticulum Stress 
The endoplasmic reticulum (ER), located in the cytoplasm, serves multiple 
functions in maintaining cell homeostasis. One of its major functions is protein synthesis, 
correct folding, modification and transportation of proteins. The ER lumen is an oxidative 
environment crucial for proper folding of proteins and formation of disulfide bonds. As 
its main role in protein folding and transport, it also contains chaperones responsible for 
the control of these proteins. Many disturbances and stresses, such as ischemic events, 
oxidative stress, calcium disturbances and inhibition of protein glycosylation, can alter 
ER’s functions causing an accumulation of unfolded proteins. When the amount of 
unfolded proteins exceeds the number of chaperones needed to refold these proteins it 
causes ER stress (Xu et al. , 2005; Rissanen et al. , 2006). For cells to cope with this 
stress they activate an evolutionary conserved response known as the unfolded protein 
response (UPR). The initial intent of the UPR is to restore correct protein folding and 
function and re-establish ER homeostasis. However, under prolonged stress, when these 
adaptations fail, the ER initiates pro-apoptotic pathways thus triggering cell suicide 
(Oyadomari et al. , 2004). The three major ER stress triggered apoptotic proteins are the 
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inositol-requiring enzyme 1 (IRE1), the PKR-like ER kinase (PERK) and the activating 
transcription factor-6 (ATF-6) (Korennykh et al. , 2009; Korennykh et al. , 2012).  
The IRE1 contains both serine/threonine kinase domains and an endoribonuclease 
domain. In mammals, IRE has been characterized to have two genes, IRE1α and IRE1β. 
IRE1α is ubiquitously expressed in all tissues, whereas the IRE1β is only expressed 
selectively in intestinal and respiratory epithelial cells (Martino et al. , 2013). The IRE1α 
plays a critical role in splicing the X-box-binding protein 1 (XBP1) and has been 
demonstrated in deletion studies to play a crucial role in murine embryonic development, 
differentiation, function, and survival of many cell types which secrete large amounts of 
protein (Wu et al. , 2015). Accumulation of unfolded proteins stimulates activation of 
IRE1α and XBP1 splicing through its ribonuclease domain, which then translocates to the 
nucleus and acts as a potent transcription factor of pro-apoptotic mediators (Hetz et al. , 
2011). In addition, it can also stimulate activation of Apoptotic signaling kinase-1 
(ASK1) which causes downstream activation of stress kinases that promote apoptosis 
(Ron et al. , 2008). Moreover, IRE1α also triggers pro-inflammatory responses in the ER 
through direct binding with adaptor protein tumor necrosis factor alpha (TNFα) receptor-
associated factor 2 (TRAF2) and subsequent activation of the nuclear factor-kappaβ (NF-
κβ) and c-Jun N-terminal kinase (JNK) pathways (Xu et al. , 2005; Cao et al. , 2014). 
The second effector protein, PERK, once activated induces its 
autophosphorylation and activates the kinase domain responsible for phosphorylating and 
inactivating the eukaryotic translation initiation factor 2 subunit α (eIf2α) (Donnelly et al. 
, 2013), thus shutting down the mRNA translation. PERK activation and phosphorylation 
of eIF2a is linked with an increased translation of the mRNA encoding the initiation of 
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activating transcription factor 4 (ATF4). The ATF4 is a transcription factor which 
induces several genes involved in acid metabolism, antioxidant stress and protein 
secretion (Rouschop et al. , 2010; Rzymski et al. , 2010). ATF4 can also induce the pro-
apoptotic effector CCAAT/enhancer-binding homologous protein (CHOP), that activates 
apoptosis (Oyadomari et al. , 2004; Jager et al. , 2012). 
Finally, activation of ATF6 triggers a slightly different mechanism compared with 
IRE1α and PERK. Accumulation of unfolded proteins activates ATF6 which causes it to 
translocate from the ER membrane to the Golgi apparatus where proteases cleave it, thus 
releasing it into the cytosol where it begins to regulate gene expressions causing an 
increase in XBP1 levels (Yamamoto et al. , 2007). 
Among the three UPR proteins, IRE1α is the key molecule responsible for cell 
fate as there is evidence that it is the only protein that can directly bind to the misfolded 
proteins and trigger a signaling response. Numerous studies show evidence that supports 
this concept, including structural studies, protein interaction studies and peptide 
interaction studies (Gardner et al. , 2011). 
 
Apoptosis 
The UPR is an important adaptive mechanism to protein misfolding, however, 
prolonged ER stress leads to the activation of pro-apoptotic UPR signaling which plays a 
critical role in pathological conditions. One of the major contributing proteins to 
apoptosis that is activated as a result of ER stress is IREα. The IRE1α-XBP1 pathway is 
required for normal development and function, however, increasing evidence suggests 
that IRE1α may contribute to apoptotic cell death (Cao et al. , 2014). It can do so via 
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several different ways. First, it can activate the JNK pathway through direct interaction 
with TRAF which inhibits Bcl-2 and hence inhibits its anti-apoptotic effects (Cao et al. , 
2014). Second, IRE1α may bind Bax and Bak on the ER membrane and initiate a 
mitochondrial dependent cascade (Cao et al. , 2014). IRE1α has also been linked to 
activation of two pro-apoptotic molecules, PUMA and BH3 (Cao et al. , 2014). More 
recently, IRE1α has also been shown to degrade specific microRNAs that target caspase 
2 and hence boosting caspase dependent apoptosis (Cao et al. , 2014). 
 
Oxidative Stress 
There are several ways the ER may cause reactive oxygen species (ROS) 
production. Firstly, in the ER lumen the correct folding of proteins requires formation of 
disulfide bonds to be able to stabilize tertiary and quaternary structures. Therefore, the 
lumen has a highly oxidized environment which is needed for bond formation (Cao et al. 
, 2014). Evidence suggests that oxidative protein folding is an important source of ROS 
production (Cao et al. , 2014). ROS can be generated as a byproduct of protein folding, 
mitochondrial respiration and detoxification.  
Protein folding is catalyzed by oxidoreductases such as protein disulfide 
isomerases (PDI). During bond formation, PDI transfers electrons to an acceptor to begin 
another cycle of bond formation. The acceptor then transfers these electrons to molecular 
oxygen and produces H2O2, which is major ROS produced in the ER lumen. Another 
inducer of ROS production is NADPH oxidase 4 (Nox4). Nox 4 can physically interact 
with PDI causing an increase in ROS generation. Studies have shown that under stress 
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Nox4 levels are increased and at the same time ROS generation is also increased 
(Zeeshan et al. , 2016). 
It has been reported that ROS production results mainly from three ER-electron 
coupling systems such as PDI and ERO1α, intra ER-GSSG/GSH and the NADPH-450 
Reductase – Cytochrome P450 (NPR-CYP) complex. However, the majority ROS 
produced in the ER is from the microsomal monooxygenase (MMO) system which is 
composed of the NPR-CYP complex. It is responsible for the production of superoxide 
anion radicals and H2O2. The leakage of electrons during electron transfer between NPR 
to CYP plays an important role in ROS generation. Increased P4502E1, a member of the 
CYP family, protein activity and expression has been linked with ROS generation and 
reported in several animal models (Kim et al. , 2009; Henke et al. , 2011). Inhibitors of 
P4502E1 have shown protection against ethanol-induced hepatic injury (Gouillon et al. , 
2000). As a result, P4502E1 activation has led to increased levels of ROS. Further 
research is required to examine its mechanisms, but it is evident that liver injury and 
insulin resistance both involve P4502E1. Another potent suppressor of P4502E1 
expression was shown to be Bax Inhibitor-1 (BI-1). Kim and colleagues showed that in 
the presence of BI-1, the levels of P4502E1 were significantly reduced thus ameliorating 
ER stress induced ROS accumulation in in vitro experiments using Neo cells (Kim et al. , 
2009). 
ROS may also be generated via release of calcium from the ER.  This causes an 
increase in mitochondrial calcium  which alters metabolism and eventually causes ROS 
production (Gorlach et al. , 2006). Increase in ROS overloads the mitochondria and 
stimulates it to work faster thus consuming more oxygen. An increase in oxygen 
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consumption will activate nitric oxide synthase which will then inhibit the activity of 
complex IV further increasing ROS production (Xu et al. , 2004; Murphy 2009; Meares 
et al. , 2011). 
 
Inflammation 
ER stress can contribute to a wide variety of inflammatory processes. In the CNS, 
ER stress may induce inflammation which can produce interferon-gamma and apoptosis 
can occur as a direct result (Zhang et al. , 2008). ER stress is also observed in the lungs 
where it is associated with  increase in CHOP and  subsequent ROS accumulation and 
cell death (Endo et al. , 2006). During ER stress, there is also a release of calcium which 
activates inflammasomes through an inositol triphosphate (IP3)-mediated mechanism that 
releases the calcium stored in the ER, resulting in accumulation of ROS (Zeeshan et al. , 
2016). In addition, the accumulation of misfolded proteins has been linked with 
inflammatory processes in bowel disease and many autoimmune diseases (Garg et al. , 
2012). Hence, targeting inflammation with anti-inflammatory drugs has shown promise 
against ER stress induced injury (Yamazaki et al. , 2006). 
The UPR may also initiate inflammatory cascades thus triggering pro-
inflammatory protein signaling. These include NF-kβ and MAPKs. In studies, they were 
triggered from eIF2 phosphorylation from PERK signaling, as depressing mRNA 
translation caused decreased levels of NF-kβ in cytosol (Lin et al. , 2007; Lin et al. , 
2013; Lin et al. , 2014). Another UPR protein involved in inflammatory responses is 
IRE1α. It can recruit the inflammatory marker, TRAF2, which can then couple IRE1α 
activation with various inflammatory pathways (Cao et al. , 2014).  
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In addition to inflammatory responses from UPR proteins, there are other 
signaling pathways that respond to ER stress and induce inflammation. ER stress and 
inflammation are connected via several pathways such as ROS, release of calcium, 
activation of NF-kβ and MAPK. It is well known that ROS are important mediators to 
inflammation (Raha et al. , 2000).  
Correct protein folding in the ER is an energy consuming mechanism and highly 
oxidative process. During formation of disulfide bonds, to manufacture tertiary and 
quaternary protein structures, there is a large amount of electron flow and utilization of 
oxygen, which produces ROS (Tu et al. , 2002). Therefore, an increase in protein folding 
in the ER is corelated with ROS production and subsequent inflammation. Moreover, 
during ER stress, there is a release of calcium into the cell which causes depolarization of 
mitochondrial membrane, thus disrupting electron transport resulting in ROS. This cycle 
of calcium release, ROS production and accumulation of misfolded proteins work in 
conjunction to activate pathways that lead to inflammation (Malhotra et al. , 2007; Zhang 
et al. , 2008). 
 
Endoplasmic Reticulum Stress Suppressors 
The Transmembrane Bax Inhibitor-1 (TMBIM) Protein Super Family 
The Bax Inhibitor-1 (BI-1) is an evolutionary conserved protein which is part of 
the TMBIM protein family involved in cytoprotection. Members of this protein family 
are hydrophobic in nature and hence reside on the ER membrane, Golgi or plasma 
membrane. The TMBIM family are composed of five highly conserved orthologues of 
BI-1 which are referred to as TMBIM family of proteins, BI-1 family or Lifeguard 
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family: GRINA/TMBIM3 (glutamate receptor ionotropic NMDA protein 1), BI-
1/TMBIM6, TMBIM2/Lfg/FAIM2, GHITM/TMBIM5 (growth hormone-inducible 
transmembrane protein), RECS1/TMBIM1 (responsive to centrifugal force and shear 
stress gene 1 protein) and  GAAP/TMBIM4 (Golgi antiapoptotic-associated protein) 
(Zhou et al. , 2008; Rojas-Rivera et al. , 2015).  
Among these proteins, it has been reported that BI-1/TMBIM6, GRINA/Lfg-1, 
Lfg-2/FAIM2 and Lfg-4/GAAP play a role in apoptosis (Hu et al. , 2009), however, 
TMBIM6/BI-1 is the best described member of the family and has several reports of its 
anti-apoptotic activities (Hu et al. , 2009; Rojas-Rivera et al. , 2015). 
 
Bax Inhibitor-1 (BI-1/TMBIM6) Protein Family 
The BI-1 is an evolutionary conserved protein first discovered in yeast and seen to 
be widely expressed in tissues such as the heart, lungs, liver, stomach, colon, kidney, 
brain, placenta, skeletal muscle and pancreas (Xu et al. , 1998; Grzmil et al. , 2006). It 
has been observed that BI-1’s levels vary in these organs during various stages of life. 
For example, BI-1 was shown to peak during times of high apoptosis (Jean et al. , 1999; 
Chae et al. , 2004), thus indicating a possible link between BI-1 and cell death.  
BI-1 contains six alpha-helix transmembrane domains with both of its N and C 
terminus exposed to the cytosol. Its protective role has been mapped to its C terminus, as 
deletion studies of the C terminus abrogated BI-1’s ability to suppress Bax induced cell 
death in yeast (Kawai-Yamada et al. , 2004).  
It was named as Bax Inhibitor-1 due to its functional effect to suppress cell death 
via inhibition of Bax gene but not because of a direct physical interaction with Bax (Xu et 
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al. , 1998). There are several studies that show evidence of BI-1’s ability to regulate the 
intrinsic pathways but not the Fas and TNFα induced extrinsic pathways. It was reported 
that overexpression of BI-1 in interleukin-3 dependent pro-B lymphocytes attenuated 
apoptosis induced from intrinsic pathway inhibitors (Xu et al. , 1998). Transfection of BI-
1’s antisense induced apoptosis in human embryonic kidney cells regardless of the 
stressors (Xu et al. , 1998). Additionally, it was reported that BI-1’s effects are caspase 
independent, as administering tunicamycin to BI-1 overexpressing cells in the presence of 
a caspase inhibitor did not cause translocation of Bax to mitochondria (Chae et al. , 
2004). However, when BI-1 overexpressing cells were treated with staurosporine with the 
caspase inhibitor, it showed translocation of Bax to mitochondria (Chae et al. , 2004). 
This indicates that BI-1’s anti-apoptotic activity is more sensitive to ER stress inducing 
agents (Robinson et al. , 2011). 
 
Bax Inhibitor-1 Like Proteins 
TMBIM1 or Lifeguard 3. The TMBIM1 is also known as Lifeguard-3 (Lfg-3) or 
RECS (Responsive to centrifugal force and shear). It is a seven helix transmembrane 
protein localized to endosomal and lysosomal membranes and expressed in almost all 
tissues (Hu et al. , 2009). It was shown to play a role in vascular remodeling as there 
were no abnormalities in Lfg-3 knockout mice (Zhao et al. , 2006), however in aged 
animals it caused aortic dilatation (Zhao et al. , 2006). 
TMBIM2 or Lifeguard 2. TMBIM2 is also predicted to contain seven helix 
transmembrane domain and is located in Golgi and ER. It is predominantly expressed in 
nervous system (Schweitzer et al. , 1998), and specifically, in dendritic processes and 
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synapses. In contrast to BI-1, TMBIM2 protects from cell death induced by the extrinsic 
pathway, Fas, but not TNFα (Somia et al. , 1999; Fernandez et al. , 2007). It was reported 
that inhibition of TMBIM6 with shRNA increased sensitivity of neural cells to Fas 
induced cell death (Fernandez et al. , 2007).  
TMBIM3 or Lifeguard 1. It was recently demonstrated that, like BI-1, TMBIM3 
resides on the ER membrane and co-immunoprecipitation experiments revealed its 
physical interaction with BI-1 (Rojas-Rivera et al. , 2015). Studies showed that knocking 
down TMBIM-3 in BI-1 wild type cells did not cause spontaneous cell death, but in 
contrast, knocking down TMBIM-3 in BI-1 knockout cells led to appearance of cell death 
features (Rojas-Rivera et al. , 2012). ER stress may trigger upregulation of 
TMBIM3/Lfg1 through PERK dependent mechanism (Hetz et al. , 2011). In conclusion, 
TMBIM3 and TMBIM6 may have synergistic function for anti-apoptotic activity 
however there is very little information regarding this protein and its signaling 
mechanism is unclear. 
TMBIM4 or Lifeguard 4. TMBIM4 is identified as a Golgi anti-apoptotic 
protein and housekeeping gene (Lee et al. , 2007). It is widely expressed in tissues and 
has shown close resemblance to BI-1. TMBIM4 can inhibit apoptosis triggered by 
intrinsic and extrinsic stimuli (Gubser et al. , 2007) and can reduce calcium stores (de 
Mattia et al. , 2009). It was shown that inhibition of Lfg-4 caused apoptosis and was seen 
to also be upregulated in human breast cancer cells (van 't Veer et al. , 2002). 
Lifeguard 5. Found predominantly in eutherian mammals and not in 
invertebrates, Lifeguard 5 is predicted to have eight transmembrane helices (Hu et al. , 
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2009). It is reported as TMBIM1 because of its great resemblance. In mouse models,  it is 
expressed only in the adult testis (Hu et al. , 2009).  
 
Bcl-2/Bcl-Xl 
These proteins are also localized to the ER membrane and are protective against 
ER stress. The main mechanism via which Bcl-2 works is believed to be through a 
decrease in ER levels of calcium via IP3Rs. 
 
MicroRNAs 
New emerging data has shown that microRNAs may either modulate ER stress or 
be activated by ER stress (Sano et al. , 2013). The PERK mediated activation of miR30c 
is stimulated upon ER stress which is correlated with downregulation of XBP1 (Byrd et 
al. , 2012). miR211 has also been identified as a PERK target that promotes cell survival. 
It was reported that miR221 is associated with CHOP mediated apoptosis during ER 
stress (Behrman et al. , 2011). As such, ER stress apoptosis was reported to be enhanced 
by miR221mimics and attenuated by miR221 inhibitors. Additionally, it was illustrated 
that CHOP regulates miR708 (Upton et al. , 2012) and spliced XBP1 was necessary for 
stress associated miR346 induction which regulate immune responses. 
 
Bax Inhibitor-1 and Endoplasmic Reticulum Stress  
BI-1 as a Regulator of Apoptosis 
As the ER is responsible for correct protein folding and maturation of proteins as 
well as a regulation of calcium, any unfavorable environment may disrupt the ER 
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function inducing ER stress and the UPR. The main function of the UPR is to allow cells 
to adapt to different stresses. In the event that this is not resolved, and the stress is 
prolonged it will result in calcium release, promoting apoptosis and pro-apoptotic ER 
signaling. 
Reports show evidence of BI-1’s protective effects in cell culture experiments 
where, cells overexpressing BI-1 that were challenged with ER stress inducers, or during 
OGD and ischemic reperfusion, did not show any characteristics of apoptotic changes 
(Chae et al. , 2004). There was no caspase activation, no blebbing, no formation of 
apoptotic bodies. Inversely, cells lacking BI-1 exhibited sensitivity to the same ER 
stresses (Chae et al. , 2004). Thus BI-1 may aid to inhibit ER stress signaling pathways 
(Chae et al. , 2004; Bailly-Maitre et al. , 2006).  
BI-1 was shown to interfere with all three ER signaling pathways, in particular, it 
was shown to be able to physically bind to IRE1α thereby blocking its RNase activity 
(Lisbona et al. , 2009). BI-1 overexpressing cells showed a decrease in levels of IRE1α as 
well as its downstream factor XBP1 (Lee et al. , 2007). BI-1 was reported to suppress 
IRE1α activity by forming a complex in both fly and mouse models of ER stress (Sano et 
al. , 2013). Knocking out TMBIM6 gene, responsible for BI-1 production, caused 
hyperactivity of the IRE1α pathway, while cells overexpressing BI-1 showed to inhibit 
IRE1α kinase and endoribonuclease activity. In addition, deletion of the C terminus of 
BI-1 failed to bind to IRE1α and hence did not suppress IRE1α activity (Sano et al. , 
2013). Additionally, BI-1 deficiency also increased XBP1, a major downstream effector 
of IRE1α. In mice knockout studies, it was shown that mice were viable and developed 
normally despite a deficiency in TMBIM6/BI-1 (Sano et al. , 2013; Urra et al. , 2013). 
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However, they were more susceptible to tissue injury induced by stroke, ischemia-
reperfusion and experimental ER stress in brain, liver and kidney (Sano et al. , 2013).  
Although BI-1 was not shown to interact with PERK or ATF6, it still affected 
their signaling pathways (Lee et al. , 2007). Lee and colleagues reported that eIF2α levels 
decreased when BI-1 is overexpressed, indicating that it may block PERK pathway via 
unknown mechanisms (Lee et al. , 2007). In addition, BI-1 was also shown to decrease 
ATF6 cleavage thus also blocking its activity (Lee et al. , 2007).   
 
BI-1 as a Regulator of Oxidative Stress and Inflammation 
During times of stress, such as after HI insult, ROS production and accumulation 
is significantly increased in the cell thus culminating in oxidative stress and the release of 
ROS. This release of ROS surrounds tissue and causes damage, potentially promoting 
inflammatory processes (Duval et al. , 2003; Kopprasch et al. , 2003).   
The main source of ROS production in the ER is from the microsomal 
monooxygenase (MMO) system composed of NADPH-P450 reductase (NPR) and the 
cytochrome P450 (CYP) members (Nieto et al. , 2002; Robinson et al. , 2011). 
Specifically, the CYP member, P4502E1, is known to produce significant amount of 
ROS such as H2O2 (Nieto et al. , 2002). 
 It is now known that BI-1 may regulate ER stress induced ROS production via two 
mechanisms. Firstly, it can influence Nuclear Factor Erythroid 2-Related Factor 2 (Nrf-2) 
upregulation, which is a redox sensitive transcription factor that controls expression of 
different anti-oxidant enzymes, such as heme oxygenase-1 (HO-1). Cells overexpressing 
BI-1 were shown to increase Nrf-2 levels, and subsequently HO-1 levels, which blocked 
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ROS (Lee et al. , 2007). Secondly, BI-1 can directly interact with NPR though its C 
terminus, thus altering the electron flow between NPR-CYP and destabilizing this complex 
resulting in blockage of ROS (Kim et al. , 2009).  Co-immunoprecipitation studies have 
revealed that BI-1 is in close proximity and has high affinity for NPR in vivo but to a lesser 
extend for P4502E1 (Kim et al. , 2009; Watanabe et al. , 2009). However, BI-1 can regulate 
P4502E1 activity, by binding to NPR and disrupting the flow of electrons between NPR 
and CYP hence lowering P4502E1 activity and its ability to produce ROS (Kim et al. , 
2009; Yang et al. , 2010; Henke et al. , 2011). The C terminus of BI-1 is required for BI-1 
to bind to NPR and hence to disrupt this complex. Adding an antibody raised against the 
BI-1’s C-terminus or in a C terminus BI-1 mutant abrogated the inhibitory effect of BI-1 
(Watanabe et al. , 2009; Li et al. , 2014). Other studies also showed that deletion of C 
terminus of BI-1 had less inhibition of P4502E1 induced ROS production and there was 
no NPR binding (Kim et al. , 2009; Watanabe et al. , 2009; Li et al. , 2014).  Despite the 
clear functional connection between BI-1 and P4502E1, a direct interaction of the two 
proteins was not shown. 
 
Specific Aims 
Hypoxic-ischemic (HI) brain injury remains a leading cause of mortality and 
morbidity for infants, affecting between 2-4 from 1000 full-term births, and nearly 60% 
of premature infants (Vannucci et al. , 1997; Volpe 2001). Among survivors, 20-40% 
develop significant neurological impairments, associated with life-long medical, social, 
and emotional difficulties (Bracewell et al. , 2002; Ferriero 2004; van Handel et al. , 
2007; Zanelli et al. , 2011). Numerous attempts to reduce HI-induced consequences have 
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failed in the clinical setting. In order to improve future outcomes, it is imperative to 
explore different therapeutic targets to either amplify or replace current therapeutic 
strategies.   
Endoplasmic reticulum stress (ER) is a major pathology encountered after HI, 
associated with dysregulation of protein folding with downstream effects on apoptosis 
and inflammation which have been implicated in a variety of disease processes (Kaser et 
al. , 2008; Li et al. , 2012; Chaudhari et al. , 2014; Li et al. , 2015; Yang et al. , 2015). HI 
induced ER stress up-regulates several stress sensors’ signaling pathways, primarily, the 
inositol requiring enzyme-1 alpha (IRE1α) signaling pathway (Madeo et al. , 2009; Sano 
et al. , 2013). ER stress is also associated with reactive oxygen species (ROS) 
accumulation, mainly from the NADPH-dependent cytochrome P450 reductase (NPR) 
and P4502E1 (CYP) complex. CYP has been linked as one of the main players in ROS 
generation (Kim et al. , 2009). 
Bax-inhibitor 1 (BI-1) protein, mainly expressed on ER membrane, has been 
shown to play a major role in inhibiting ER stress related apoptosis (Xu et al. , 1998; 
Watanabe et al. , 2009) and inflammation. BI-1 is encoded by the TMBIM6 gene, part of 
the Bcl-2 family of proteins that can directly bind to Bcl-2 and form a complex, resulting 
in inhibition of pro-apoptotic molecules (Xu et al. , 1998; Watanabe et al. , 2009; Iwata et 
al. , 2011; Robinson et al. , 2011). Evidence from previous in vitro studies supports BI-
1’s ability to directly bind to IRE1α and inhibit this pro-apoptotic signaling pathway 
induced after ER stress (Chae et al. , 2004; Lisbona et al. , 2009; Bailly-Maitre et al. , 
2010). Furthermore, it has been shown that BI-1 can reduce ROS accumulation by 
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disrupting the electron transport between NPR and CYP and by simultaneously activating 
Nrf-2 (Lee et al. , 2007; Kim et al. , 2009; Henke et al. , 2011).  
This proposal will be the first to show BI-1’s anti-apoptotic and anti-
inflammatory effects in an animal stroke model, by overexpression of the BI-1 protein 
with intracerebroventricular (icv) injection of human adenoviral-TMBIM6 (Ad-
TMBIM6) vector and elucidate the pathways associated with BI-1’s protective effects.  
The specific objective of this proposal is to establish BI-1’s anti-apoptotic and 
anti-inflammatory effects in an in vitro oxygen glucose deprivation (OGD) model, as 
well as in an in vivo neonatal hypoxia ischemia (HI) rat model, followed by subsequent 
clarification of the mechanisms via which it confers its protective properties. Our central 
hypothesis is that (1) transfection of PC-12 cells with Ad-TMBIM6 vector will improve 
cell viability after OGD (2) in vitro OGD model will help determine the major pathways 
involved in BI-1’s protective effects (3) overexpression of the BI-1 protein in the brain, 
via Ad-TMBIM6 injection will improve recovery after neonatal HI by reducing ER stress 
induced (a) neuronal apoptosis via inhibition of IRE1α signaling pathway and (b) 
oxidative stress induced inflammation via dissociation of the NPR-CYP complex and 
subsequent inhibition of ROS.  This hypothesis will be tested with the following specific 
aims: 
 
Aim 1 
To determine whether BI-1 upregulation exerts its anti-apoptotic effects via the 
IRE1α signaling pathway in an in vitro and in vivo neonatal HI rat model. This aim 
will examine the effects of BI-1 overexpression on IRE1α and PERK signaling, as well as 
 27 
examine BI-1’s long-term effects on functional deficits after HI. ER stress, as a result of 
HI injury, is reported to trigger three main signaling pathways: IRE1α, PERK and ATF6, 
which under pathological conditions lead to apoptosis. Studies have shown that 
overexpression of BI-1 in cells in response to ER stress inducers, or during OGD and I/R 
injury, can attenuate ER stress induced apoptotic phenotypes.  BI-1 knockout cells 
showed the opposite effects, indicating that BI-1 aids to inhibit ER stress signaling 
pathways (Chae et al. , 2004). BI-1 can also physically bind to and inhibit IRE1α (Bailly-
Maitre et al. , 2010) and its downstream molecules such as XBP1 (Lisbona et al. , 2009; 
Bailly-Maitre et al. , 2010). Several in vitro studies have been done in TBI, MCAO and 
hepatic ischemia/reperfusion models which present data in support of BI-1’s anti-
apoptotic effects (Bailly-Maitre et al. , 2006; Krajewska et al. , 2011; Ma et al. , 2014). It 
is unclear whether BI-1 exerts its anti-apoptotic effect mainly via IRE1α inhibition or 
whether it also plays a role in inhibiting PERK. This aim will help determine whether 
IRE1α is the major pathway via which BI-1 exerts its neuroprotective role and translate 
this in vitro finding to our in vivo studies.  
 
Aim 2 
To investigate the anti-oxidative effects of BI-1 overexpression and the signalling 
pathways involved in an in vitro and in vivo neonatal HI rat model. This aim will 
examine BI-1’s role in oxidative stress, focusing on BI-1’s ability to dissociate the NPR-
CYP complex and activate Nrf-2 transcription factor resulting in attenuation of ER stress 
induced ROS accumulation and subsequent inflammation.  
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The major source of ER stress induced ROS accumulation is from the microsomal 
monooxygenase (MMO) system which is composed of cytochrome P4502E1 (CYP), 
NADPH-P450 reductase (NPR) and some phospholipids (Kim et al. , 2009). The leakage 
of the electron transfer between NPR and CYP results in the accumulation of ROS. Our 
specific hypothesis is that BI-1 will reduce ER stress induced ROS accumulation and 
subsequent inflammation via: (1) coupling with NPR and disrupting the NPR-CYP 
complex; (2) upregulating the anti-oxidant transcription factor, Nrf-2, which leads to 
increase in HO-1 production. HO-1 is a rate-limiting enzyme shown to be able to 
attenuate ROS accumulation. Overexpression of BI-1 should increase HO-1, which 
should subsequently decrease the UPR by limiting oxidative dysregulation of the ER. 
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Figure 1.1 Schematic Representation of the central hypothesis and specific aims 
Aim 1 will investigate the effects of overexpression of BI-1on the stress sensor protein, 
IRE1α in HI model. The signaling pathway molecules will be measured as well as the 
apoptotic markers in the brain and assess infarct area. Aim 2 will study the effects of 
overexpression of BI-1 on the NPR-CYP complex, responsible for production of ROS, and 
also measure the levels of anti-oxidant enzymes and inflammatory mediators. 
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Abstract 
A wide variety of conditions may contribute to oxidative protein folding 
processes in the endoplasmic reticulum (ER) which cause ER stress. Three major 
pathways, referred to as the unfolded protein response (UPR), transmit information 
regarding protein folding status in the ER lumen to help cells cope with altered protein 
synthesis demands. However, after hypoxic ischemic (HI) injury, prolonged activation of 
the UPR triggers pro-apoptotic signaling causing cells to undergo apoptosis.  
Here we identified Bax Inhibitor-1 (BI-1), an evolutionary protein encoded by the 
Transmembrane Bax inhibitor Motif Containing 6 (TMBIM6) gene, as a novel modulator 
of ER stress induced apoptosis after HI brain injury in a neonatal rat pup.  BI-1 may 
modulate the UPR response by a direct physical interaction with the stress sensor, IRE1α, 
and via indirect inhibition of the PERK receptor. The main objective of our study is to 
overexpress BI-1 using viral-mediated gene delivery of human adenoviral-TMBIM6 (Ad-
TMBIM6) vector, to investigate its anti-apoptotic effects as well as elucidate its signaling 
pathways in an in vitro oxygen glucose deprivation (OGD) model and in an in vivo 
neonatal HI rat model. 
Cells transfected with Ad-TMBIM6 vector improved cell viability, while 
manipulation of both IRE1α and PERK determined IRE1α as the predominant pathway 
via which BI-1 confers neuroprotection after OGD. Our in vivo data showed similar 
results in ten-day old unsexed Sprague-Daley rat pups that underwent right common 
carotid artery ligation followed by 1.5h of hypoxia. Rat pups injected with Ad-TMBIM6 
vector showed a reduction in percent infarcted area and improved long-term neurological 
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outcomes, as well as attenuated neuronal degeneration and reduced ER stress induced 
neuronal apoptosis via inhibition of IRE1α signaling pathway.  
This study showed a novel role for BI-1 and ER stress in the pathophysiology of 
HI and provided a basis for BI-1 as a potential therapeutic target. 
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Introduction 
Hypoxic-ischemic (HI) brain injury is a result of hypoxemia or reduced cerebral 
blood flow (Ferriero 2004) causing pulmonary immaturity, respiratory distress syndrome, 
hypercapnia, hypo perfusion, seizures and long-term cognitive and behavioral deficits 
(Wirrell et al. , 2001; Bracewell et al. , 2002; Ferriero 2004; Bartha et al. , 2007; Yang et 
al. , 2015). HI affects 1-4 cases per 1000 births (Vannucci 2000) with morbidity rates 
ranging between 10-80% based on the severity of injury (Kaser et al. , 2008; Chaudhari 
et al. , 2014). Current treatments include hypothermia, anticonvulsants, fluid and 
electrolytes management, and drugs such as atropine and epinephrine but (Zanelli et al. , 
2011; Jacobs et al. , 2013) despite the efficacy of some of the treatments, 40-50% of 
treated patients still have persistent neurodevelopmental deficits (Barrett et al. , 2007; 
Zanelli et al. , 2011). 
The Endoplasmic reticulum (ER) is responsible for correct protein folding and 
protein function (Zhang et al. , 2014). Protein folding is crucial for cell survival. 
However, under pathological conditions, such as HI, there is an accumulation of unfolded 
proteins beyond the capacity of the chaperons to fold the protein causing ER stress (Xu et 
al. , 2005; Barrett et al. , 2007; Zhang et al. , 2014). This condition triggers the unfolded 
protein response, resulting in the activation of pro-apoptotic cascades (Madeo et al. , 
2009; Sano et al. , 2013).  The three transmembrane receptor pathways activated as a 
result of ER stress are (1) Inositol-requiring protein 1 alpha (IRE1α), (2) RNA-dependent 
protein kinase-like ER kinase (PERK) and (3) activating transcription factor 6 (ATF6) 
(Sano et al. , 2013). The main function of these receptors is to alleviate stress and restore 
normal cell function by reducing misfolded proteins. However, under prolonged ER 
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stress, these pathways become over activated resulting in incorrect signalling, leading to 
apoptosis (Tabas et al. , 2011). This is further exacerbated by subsequent reactive oxygen 
species (ROS) accumulation.  
The Bax-inhibitor 1 (BI-1) protein mainly resides in the ER membrane and is 
encoded by the TMBIM6 gene (Xu et al. , 1998; Li et al. , 2014; Rojas-Rivera et al. , 
2015).  BI-1 is part of the Bcl-2 family of proteins that regulates pro-apoptotic molecules 
such as Bax by directly interacting with Bcl-2 as shown in in vivo experiments (Xu et al. , 
1998; Watanabe et al. , 2009; Iwata et al. , 2011). Studies have shown that cells 
overexpressing BI-1, that have been under ER stress inducers, or during OGD and I/R 
injury, did not show apoptotic phenotypes; whereas, BI-1 knockout cells showed the 
opposite effects, indicating that BI-1 aids to inhibit ER stress signaling pathways (Chae et 
al. , 2004). BI-1 can also physically bind to and inhibit IRE1α (Bailly-Maitre et al. , 
2010) and its downstream molecules such as XBP1 (Lisbona et al. , 2009; Bailly-Maitre 
et al. , 2010). Several in vitro studies have been done in TBI, MCAO and hepatic 
ischemia/reperfusion models which present data in support of BI-1’s anti-apoptotic 
effects via inhibition of ER stress and the subsequent  pro-apoptotic pathways (Bailly-
Maitre et al. , 2006; Krajewska et al. , 2011; Ma et al. , 2014).  
It is unclear whether BI-1 exerts its anti-apoptotic effects mainly via IRE1α inhibition or 
whether it also plays a role in inhibiting the PERK receptor; Using an in vitro oxygen 
glucose deprivation (OGD) model, we sought to determine whether IRE1α is BI-1’s 
major pathway which we can then translate to our in vivo model. Our specific objective is 
to establish that overexpression of BI-1 protein, via administration of human adenoviral-
TMBIM6 (Ad-TMBIM6) vector, will attenuate the morphological and neurological 
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consequences post neonatal HI by attenuation of ER stress induced pathways. Elucidating 
BI-1’s mechanism in vitro and translating it to our in vivo HI model is crucial and will 
help to provide a basis for BI-1 as a potential therapeutic target in clinics. 
 
Materials and methods 
In Vitro Experiments  
Rat pheochromocytoma cells, PC-12 cells, were used at passage 6 through 9.  Cells 
were grown as previously described(Dickson et al. , 1986). 
 
Oxygen Glucose Deprivation Model 
Cells were replaced with glucose deprived media after which they were placed in 
hypoxic chamber and flushed with 1% Oxygen for 1h, 1.5h, 3h, 5h and 6h. Complete 
growth media was then added, and cells allowed to recover for 18h after which were 
prepared for cell death assay and western blotting(Agani et al. , 2002; Souvenir et al. , 
2014).  
 
Cell Death Assay 
Assessed with trypan exclusion as previously described(Souvenir et al. , 2014). 
Briefly, cells were scraped and then centrifuged for 5min after which they were re-
suspended in 10ml complete growth media. 20µl from cells was added to 20µl Trypan 
blue and well mixed and let to sit for 3min. 10µl from mixture was placed on cell counter 
slides, slides were then read using an automated cell counter. The average of 6 counts 
was used (Souvenir et al. , 2011).  
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Western Blotting for Cells 
Cells were collected 18h after OGD and stored for western blotting as previously 
described (Dominguez et al. , 2008; Souvenir et al. , 2014). Briefly, cells were 
centrifuged and then re-suspended in 1ml PBS, after which they were centrifuged one 
more time at 14000rpm for 5min. The supernatant was removed, leaving only the pellet. 
RIPA was added with protease inhibitor and pipetted thoroughly until pellet was fully 
broken down. It was then allowed to sit on ice for 20min following which it was 
centrifuged for 30min. The supernatant was harvested, and the pellet was discarded. 
Protein concentration was measured using Bradford assay and SD-PAGE electrophoresis 
was performed as previously described(Dominguez et al. , 2008). Primary antibodies: BI-
1 antibody (1:100, Abcam), anti-IRE1α antibody (1:100, Abcam), Anti-PERK antibody 
(1:100, Abcam) and Casp3/cleaved caspase 3 antibodies (1:400, cell signaling 
technology).  
 
Calculation of MOI 
To determine the total amount of infectious particles needed to infect one cell, 
Multiplicity of Infection (MOI), was calculated as follows: #cells * desired MOI= total 
PFU (or Plaque Forming Units) needed; (total PFU needed) / (PFU/ml) = total ml of 
virus needed to reach desired dose.  
 
Transfections 
siRNA transfection: Prior to transfection, cells were differentiated and allowed to 
reach 80% confluency in poly D-lysine coated 6 well plates.  siRNA was prepared 
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according to manufacturer’s protocol (Sigma-Aldrich); a stock of 10uM siRNA was 
prepared, 4ul from siRNA stock were mixed with 125µl Opti-MEM. In a separate tube, 
7µl liofectamine3000 was mixed with 125µl Opti-Mem. The two tubes were combined 
and left to sit in room temperature for 15-45min. 250µl mixture/well was applied to cells 
and an additional 1ml Opti-MEM was added. Cells were then placed in an incubator for 
5-7h, following which media was removed and replaced with normal growth media.   
CRISPR transfection: 50,000 cells were plated and allowed to grow and 
differentiate following which cells were transfected first with Ad-TMBIM6, then 700µl 
CRISPR was added 48h later. Plasmid was diluted in 200µl sterile DNase free water 
(provided) giving a concentration of 0.1µg/µl (Santa Cruz). Stock solution was further 
diluted with transfection medium to bring to desired concentration of 2µg-8µg per 
500,000 to 1 million cells. After transfection cells were placed in incubator for 5-7h 
following which media was removed and replaced with normal media and prepared for 
OGD.  
STF-083010 (IRE1α antagonist), CCT020312 (PERK agonist) and APY-29 (IRE1α 
agonist) transfection: dissolved and prepared according to manufacturer 
recommendations. STF-083010 was prepared to final concentration at 20µM or 60µM, 
CCT020312 was tested at 10µM and APY-29 was tested at 20µM and 60µM. Best dose 
was chosen at 20µM for both drugs (cell viability quantification data not shown). 
 
In Vivo Experiments 
The Institutional Animal Care and Use Committee of Loma Linda University has 
approved all protocols. The animals were cared for and all studies conducted in 
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accordance with the United States Public Health Service's Policy on Humane Care and 
Use of Laboratory Animals. Sprague Dawley rat mothers, with litters of 10~12 pups, 
were purchased from Harlan Labs (Livermore, CA). The following have been applied to 
ensure robust and unbiased experimental design and analysis of data, (A) Randomization 
& Blinding: All animals were randomly assigned to experimental groups via generation 
of random number assignment. Furthermore, all investigators were blinded to animal 
groups and the interventions that animals received. (B) Control Groups: Appropriate 
control groups were included for each intervention group. Furthermore, for siRNA 
experiments, animals were injected only siRNA or scramble, without treatment (Ad-
TMBIM6) as control. No animals were excluded apart from the normal 12% mortality 
rates for this model.  
 
Hypoxic Ischemic Rat Model 
HI surgery was performed using the established Rice Vannucci model as 
previously described (Vannucci et al. , 1997; Vannucci et al. , 2004). Briefly, P10 
unsexed Sprague-Daley rat pups were placed into a temperature-controlled chamber for 
induction of general anesthesia.  The animals were anesthetized with 3% isoflurane gas in 
air and maintained at 2.5% isoflurane in air during surgery.  Throughout the surgical and 
postoperative period, temperature was controlled with heating blankets and incubators.  
After induction of anesthesia the neck of the rats was prepared and draped using standard 
sterile techniques.  Next a small midline neck incision on the anterior neck was made 
with a No. 11 blade surgical knife (approximately 3-5 mm in length).  Using gentle blunt 
dissection, the right carotid artery was isolated and gently separated from surrounding 
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structures.  The carotid artery was then ligated with 5-O surgical suture.  After the carotid 
artery had been ligated, the skin was sutured. Rats were then allowed to recover for 1h on 
a heated blanket. Thereafter, they were placed in a 500-ml airtight jar partially submerged 
in a 37 °C water bath to maintain a constant thermal environment.  Rat pups were 
exposed to a gas mixture of 8% Oxygen and 92% Nitrogen for 90min. Thereafter, the 
animals were returned to their mothers and monitored daily.  
 
Drug Administration 
Human adenoviral TMBIM6 vector (Ad-TMBIM6) (Vector Biolabs) was injected 
intracerebroventricularly (icv) at 2µl containing 1.6x1011 PFU/ml or 1.7x1011 PFU/ml per 
injection(Bailly-Maitre et al. , 2010) at 72h, 48h and 24h pre-HI, as well as 1h post HI. 
BI-1 siRNA (Sigma-Aldrich) and IREα CRISPR activation plasmid (AP) (Santa Cruz) 
were administered icv at 48h pre-HI. 
 
Infection Area Calculation  
Animals were euthanized at 72h post HI and infarct area was assessed using 
2,3,5-Triphenyltetrazolium Chloride Monohydrate (TTC) staining. Briefly, brains were 
sectioned into 2mm slices and placed in TTC stain as previously described(Zhou et al. , 
2009; Li et al. , 2012). Red is indicative of live tissue.  
 
Behavioral Analysis 
Neurobehavior test were performed at 4 weeks using rotarod, water maze and foot 
fault. We chose these neurobehavioral tests because they effectively cover a range of 
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neurological functioning (sensation, motor function, and cognitive functioning). In 
addition, these tests have a good predictive value of impaired neurological function. The 
water maze test has been closely correlated with long-term functional deficits. Animals 
were then euthanized, and brain samples weighed and collected for histopathological 
examination.  
Foot Fault: Animals were placed on a horizontal grid floor (square size 28 x 3 
cm, wire diameter 0.4 cm) for 2 min. Foot-fault is defined as when the animal 
inaccurately places a hindlimb, and it falls through one of the openings in the grid. The 
numbers of foot-faults for each limb of each animal was recorded (Hartman et al. , 2005; 
Bouet et al. , 2010). 
Rotarod: The rotarod assesses motor impairment. Animals were placed on a 
spinning bar to test their motor function. Rats underwent stationary, constant and 5rpm 
acceleration which was recorded by (Hartman et al. , 2005; Bouet et al. , 2010).  
Water Maze: Morris water maze test assesses learning, memory, and visual 
functions (Hartman et al. , 2005; Bouet et al. , 2010). Activity of animal’s swim paths 
were recorded and measured for quantification of distance, latency, and swimming speed 
for 5 days using the Video Tracking System SMART-2000 (San Diego Instruments Inc., 
CA). Animals were then sacrificed, and brains collected for histological analysis. 
 
Western Blotting of Brain Tissue 
Western blotting was performed as previously described (Li et al. , 2015). Equal 
amounts of protein (30μg) was loaded on an 8%~12% SDS-PAGE gel and 
electrophoresed, it was then transferred to a nitrocellulose membrane (0.2μm). The 
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membrane was blocked for 1h and then incubated with primary antibodies overnight at 
4°C: BI-1 antibody (1:100, Abcam), anti-IRE1α/anti-pIRE1α antibodies (1:100, Abcam), 
Anti-XBP1 antibody (1:100, Abcam), anti-Chop antibody (1:500, Proteintech), 
Casp3/cleaved caspase 3 antibodies (1:400, cell signaling technology), anti-Bcl2 (1:500, 
Abcam), anti-bax (1:500, Abcam) and anti-ROMO1 antibody (1:100, Abcam). The 
membranes were then incubated at room temperature for 1h with horseradish peroxidase-
conjugated secondary antibodies (Santa Cruz Biotechnology) followed by 
chemiluminescence detection (GE Healthcare). The densitometric quantification of the 
bands was performed with image J software.  
 
Histology 
Brains were post-fixed in formalin, and then sectioned into 10μm thick coronal 
slices by cryostat (CM3050S; Leica Microsystems) for immunohistochemistry, Flouro-
Jade C and into 16-20μm thickness for Nissl’s staining.  
Immunofluorescence staining: Rats were anesthetized at 72h post HI and 
transcardially perfused with PBS and formalin. Brain sections were then post fixated with 
formalin for 1 day and dehydrated in 30% sucrose solution. Immunofluorescence staining 
was performed as previously described(Shi et al. , 2017). The tissue mounted on the 
slides were washed with 0.1M PBS three times for 5min then incubated in 0.3% Triton 
X-100 in 0.1M PBS for 30min at room temperature. This was then washed with 0.1M 
PBS for 5min, 3 times, and primary antibodies were applied overnight at 4°C: anti-BI-1 
antibody (1:100, Abcam), anti-IRE1α antibody (1:100, Abcam), NeuN ((1:100, Abcam), 
and CC3 (1:100, Abcam) respectively. After washing with PBS, sections were incubated 
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with appropriate secondary antibodies: anti-rabbit IgG-TR, anti-mouse IgG-FITC, anti-
goat IgG-FITC, anti-rabbit IgG-FITC (1:200) for 1h @ RT. Finally, slides were covered 
with DAPI and visualized under a fluorescent microscope and a Magna Fire SP system 
(Olympus) was used to analyze microphotographs. 
Fluoro-Jade C: 10μm brain sections were cut with cryostat (Leica LM3050S) for 
Fluoro-Jade C as previously described(Xie et al. , 2017). Slides were immersed in 1% 
sodium hydroxide dissolved in 80% ethanol for 5min, followed by being rinsed for 2min 
in 70% ethanol, then 2min in distilled water. Slides were then incubated in 0.06% 
potassium permanganate solution for 10 min, followed by 2min in distilled water, and 
then transferred into 0.0001% solution of Fluoro-Jade C (Millipore, USA) which was 
dissolved in 0.1% acetic acid. Slides were then rinsed 3 times with distilled water for 
1min. After the water was drained and slides dried, they were cleared in xylene for 1min, 
and finally cover slipped with DPX (Sigma-Aldrich, USA). 
Nissl’s staining and evaluation of brain tissue loss and ventricular area: Pups were 
euthanized at 4weeks post HI and brains were sectioned. The prepared slides (16 μm) 
were dehydrated in 95% and 70% ethanol for 1min respectively, rinsed in tap water and 
distilled water for 30sec. The slides were then stained with 0.5% cresyl violet (Sigma-
Aldrich, USA) for 2min, and washed in distilled water for 10 and 30sec. 100% ethanol 
and xylene were used to dehydrate the tissue sections 2 times for 1.5min before placing a 
coverslip with permount on the slide (Shi et al. , 2017). Image J was used to measure 
percent tissue loss.  
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Statistical Analysis 
Rats were randomly assigned to each group and the investigators were blinded from 
previous procedures.  All values will be presented as mean ± standard deviation (SD), 
and analyzed by one-way analysis of variances (ANOVA), followed by Tukey test or 
Holm-Sidak or Dunnett’s post hoc analysis. A P-value less than 5% will be considered 
significant. Sample sizes were determined by power of 0.8, α=0.05, and a 20% standard 
deviation from the preliminary results. The estimated sample size was 4 to 9/group.  
 
Results 
To Establish the Optimum Time for OGD and Optimal Multiplicity of Infection 
(MOI) Needed of Ad-TMBIM6 Vector to Successfully Transfect PC12 Cells 
Data showed a time dependent decrease in percent cell viability in cultured PC12 
cells when exposed to variable periods of OGD. Cells were exposed to 5 different OGD 
time periods ranging from 1h to 6h. Percent cell viability was significantly reduced when 
compared to control at 3h, 5h and 6h (Figure 2.1A). Optimal time for OGD exposure was 
chosen at the 3h time point to best represent severity of our in vivo HI model. 
Optimal Multiplicity of Infection (MOI) was shown to be 100MOI as it significantly 
improved cell viability compared to vehicle and to 200/1000MOI after 3h OGD (Figure 
2.1B).  
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To Determine the Effect of Ad-TMBIM6 on Percent Cell Viability in an in vitro 
OGD Model 
Cells exposed to 3h of OGD (Vehicle) showed a significantly higher percent of cell 
death when compared to control and OGD+ Ad-TMBIM6 group (Figure 2.1C-D). BI-1 
siRNA (a BI-1 inhibitor), APY-29 (20µM; IRE1α agonist) or CCT020312 (PERK 
agonist) reversed BI-1’s protective effects as seen from the significantly lower percentage 
of cell viability (Figure 2.1D). Ad-TMBIM6+PERK CRISPR(knockdown) did not 
improve cell viability when compared to OGD group. On the contrary, adding STF-
083010 (IRE1α antagonist; 20µM) to Ad-TMBIM6 showed to significantly improved cell 
viability (~85% living cells) when compared to PERK CRISPR or OGD (~40% living 
cells) group. 
Control groups, OGD+Ad-TMBIM6+scramble/or DMSO/or control CRISPR showed to 
significantly improve cell viability when compared to Vehicle group/or APY-29/or 
CCT020312/or PERK CRISPR but did not restore cell viability up to control or Ad-
TMBIM6 treated group levels.  
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Figure 2.1 Percent cell viability significantly improved after transfection of cells with 
100MOI of Ad-TMBIM6 in an in vitro OGD Model 
Time dependent decrease was seen in percent cell viability in cultured PC12 cells when 
exposed to 1h, 1.5, 3h, 5h and 6h in OGD.  Percent cell viability was significantly reduced 
when compared to control at 3h, 5h and 6h (A). Cells transfected with 100MOI  
significantly improved percent cell viability when compared to vehicle or to 200MOI and 
1000MOI at 3h of OGD (B). Representative picture showing cell morphology and density 
of cells after OGD in all groups (C). Cell death assay showed that Ad-TMBIM6 treatment 
group as well as the control groups (Ad-TMBIM6+scramble siRNA; Ad-
TMBIM6+DMSO and Ad-TMBIM6+control CRISPR) and Ad-TMBIM6+STF-083010 
significantly improved cell viability when compared to vehicle, BI-1 siRNA, APY-29, 
CCT020312 and PERK CRISPR knockdown groups (D). (Data expressed as mean +/− 
SD; *p<0.05 vs control; #p<0.05 vs vehicle; @p<0.05 vs Ad-TMBIM6 and scramble 
siRNA or vs 100MOI; ε p<0.05 vs Ad-TMBIM6 only; $p<0.05 vs BI-1 siRNA; &p<0.05 
vs APY-29; +p<0.05 vs DMSO; %p<0.05 vs CCT020312; ^p<0.05 vs STF-083010 and 
Control CRISPR. n=5-6/group using one-way ANOVA followed by Tukey multiple-
comparison post hoc analysis). 
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To Establish BI-1’s Anti-Apoptotic Effects via the IRE1α Signaling Pathway in 
an in vitro OGD Model 
To test the underlying mechanism via which BI-1 attenuated apoptosis both IRE1α 
agonist (APY-29) and antagonist (STF-083010) were used as well as PERK agonist 
(CCT020312) and antagonist (PERK CRISPR knockdown). These helped to manipulate 
both pathways to determine the dominant one. Quantification data showed that BI-1 
expression levels were significantly increased in the Ad-TMBIM6 treated group and in 
the control groups: scramble siRNA, DMSO and Control CRISPR; while BI-1 siRNA 
and APY-29 showed to reverse those effects (Figure 2.2A-B). CCT020312 and PERK 
CRISPR as well as STF-083010 showed similar expression levels of BI-1 to Ad-
TMBIM6 treatment group (Figure 2.2A-B).  
Intervening at the PERK receptor did not seem to alter BI-1 expression levels as 
CCT020312 did not show to affect BI-1 levels whereas intervening at IRE1α with APY-
29 significantly reduced BI-1’s levels (Figure 2.2B). Ad-TMBIM6, scramble siRNA + 
Ad-TMBIM6, DMSO + Ad-TMBIM6 and Control CRISPR significantly reduced 
pIRE1α, pPERK and cleaved caspase 3 (CC3) expression levels (Figure 2.2C-E) 
compared to vehicle. Meanwhile, BI-1 siRNA, APY-29, CCT020312 and PERK CRISPR 
showed to increase pIRE1α expression levels (Figure 2.2C). Expression levels of pPERK 
were significantly upregulated after OGD in vehicle group, BI-1 siRNA and CCT020312 
when compared to the rest of the groups (Figure 2.2D). While Ad-TMBIM6 and control 
groups (scramble siRNA, DMSO and Control CRISPR) significantly reduced CC3 
expression, activation of PERK with CCT020312 did not significantly upregulate CC3 
when compared to treatment or control groups (Figure 2.2E), in fact it showed to 
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significantly decrease CC3 expression levels. Furthermore, APY-29 showed to 
significantly upregulate CC3 when compared to CCT020312. In addition, STF-083010 
showed to be more effective at reducing CC3 compared to PERK CRISPR (Figure 2.2E).  
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Figure 2.2 BI-1 exerted its anti-apoptotic effects via inhibition of IRE1α in an in vitro 
OGD model 
Representative picture of western blot bands showing protein expression levels (A). 
Quantification data of bands showed that BI-1 expression levels were significantly 
increased in the Ad-TMBIM6 treatment group and in the control groups (scramble siRNA, 
DMSO and Control CRISPR), while BI-1 siRNA and APY-29 groups reversed those 
effects (B). Ad-TMBIM6 and control groups significantly reduced pIRE1α, pPERK and 
CC3 expression levels (C-E). BI-1 siRNA, APY-29, CCT020312 and PERK CRISPR 
increased pIRE1α expression levels (C). Expression levels of pPERK were significantly 
upregulated in vehicle, BI-1 siRNA and CCT020312 compared to the rest of the groups.  
PERK CRISPR effectively knocked down pPERK expression levels (D). Ad-TMBIM6 and 
control groups significantly reduced CC3 expression levels, activation of PERK with 
CCT020312 did not significantly upregulate CC3 when compared to treatment or control 
groups (E). APY-29 showed to significantly upregulate CC3 when compared to 
CCT020312. In addition, STF-083010 was more effective at reducing CC3 compared to 
PERK CRISPR (E). (Data represent +/− SD; *p<0.05 vs control; #p<0.05 vs vehicle; 
@p<0.05 vs Ad-TMBIM6 and Ad-TMBIM6+scramble siRNA; $p<0.05 vs BI-1 siRNA; 
&p<0.05 vs APY-29; +p<0.05 DMSO; %p<0.05 vs CCT020312; ^p<0.05 vs STF-083010 
and Control CRISPR. n=5-6/group using one-way ANOVA followed by Tukey multiple-
comparison post hoc analysis).   
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Expression Levels of Endogenous BI-1, IRE1α, XBP1 and CHOP in Time 
Dependent Manner post HI 
BI-1 expression levels increased in a time dependent manner, which peaked at 24h 
and then significantly decreased to sham levels at 72h post HI (Figure 2.3A-B). IRE1α 
and XBP1 expression levels significantly increased at 6h post HI and remained elevated 
until 72h post HI (Figure 2.3A, C-D). CHOP levels significantly increased at 24h post HI 
when compared to sham (Figure 2.3A, E).  
 
Low Dose Ad-TMBIM6 Administered at 48h pre-HI Reduced Infarct Area at 
72h post HI 
To test the best time of administration of Ad-TMBIM6 vector we tested 4 time points. 
Ad-TMBIM6 significantly reduced infarct area compared to vehicle treated group when 
it was administered at 48h pre-HI (Figure 2.3F). Furthermore, to evaluate dose response 
of Ad-TMBIM6 viral vector on infarct area two doses were used (1) low dose of 
1.6x1011PFU/ml and (2) a high dose of 1.7x1011PFU/ml. TTC staining results showed 
that the optimal dose for administration of the viral vector was the low dose 
(1.6x1011PFU/ml) as it proved to be more effective as it significantly reduced infarct area 
when compared to vehicle or high dose vector (Figure 2.3G).   
  
 68 
 
 
 
Figure 2.3 To Measure expression levels of endogenous BI-1, IRE1α, XBP1 and 
CHOP and determine optimum time and dose of Ad-TMBIM6 administration post 
HI 
Representative pictures of Western blot bands (A). Data showed that BI-1 expression levels 
significantly increased in a time-dependent manner from 6h to 24h, and then dropped to 
sham levels at 72h post HI (B). IRE1α inceased significantly post HI compared to sham 
and remained elevated untill 72h post HI (C). The expression of XBP1 increased post HI 
and remained elevated from 6h through 72h post HI (D). CHOP levels increased from 6h 
to 72h, peaking at 24h post HI (E).  Data expressed as mean +/- SD; *p<0.05 vs sham; # 
p<0.05 vs 6h, @ p < 0.05 vs 24h; n=4, using one-way ANOVA followed by Tukey 
multiple-comparison post hoc analysis. Optimal time of injection was at 48h pre-HI, at this 
time significantly reduced the percentage of infarcted area versus vehicle, or the other time 
points (F). Low dose of Ad-TMBIM6 (1.6x1011 PFU) viral vector significantly improved 
the percentage of infarcted area when compared to vehicle or high dose (1.7x1011 PFU) 
vector (G). (Data expressed as mean +/- SD; *p<0.05 vs sham; # p<0.05 vs vehicle, @ p < 
0.05 vs Ad-TMBIM6 (1.6x1011 PFU), n=6, using Unpaired T-Test for (F) and one-way 
ANOVA followed by Tukey multiple-comparison post hoc analysis for (G)). Blots were 
cropped to improve clarity.  
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Histological Staining at 72h post HI 
Immunofluorescence staining showed a significantly higher expression of BI-1 on 
neurons in the Ad-TMBIM6 treatment group when compared to vehicle (Figure 2.4A). 
Furthermore, IRE1α was significantly decreased in the Ad-TMBIM6 treatment group 
when compared to vehicle, but also showed co-localization with neurons (Figure 2.4B). 
In addition, staining for BI-1 on astrocytes demonstrated minimal colocalization in all 
groups (Figure 2.4C). (Green was for neuronal/astrocyte staining, Red was for BI-
1/IRE1α staining and Blue was for DAPI. Merge showed the colocalization of BI-1 or 
IRE1α on neurons/astrocytes. Scale bar = 50 μm; n=1/group).  
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Figure 2.4 Histological staining showed co-localization of BI-1 on neurons but not 
with astrocytes at 72h post HI 
Immunofluorescence staining demonstrated a significantly higher expression of BI-1 on 
neurons in Ad-TMBIM6 treatment group compared to sham or vehicle (A). Fluorescent 
levels of IRE1α was reduced in Ad-TMBIM6 treatment group when compared to vehicle 
(B). (Green was for neuronal staining, Red was for BI-1 or IRE1α staining and Blue was 
for DAPI). Merge showed the colocalization of BI-1 or IRE1α on neurons (A-B). (Scale 
bar = 50 μm; n=1/group). There was minimal co-localization of BI-1 with astrocytes (C). 
(Green was for astrocyte staining, Red was for BI-1 and Blue was for DAPI). Merge 
showed the colocalization of BI-1 on astrocytes (C). (Scale bar = 50 μm; n=1/group). 
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Ad-TMBIM6 Improved Long-term Neurological Function at 4weeks post HI 
To test the effects of Ad-TMBIM6 treatment on the long-term neurological 
impairments induced by neonatal HI, neurological function was assessed by foot fault, 
rotarod and water maze at 4weeks post HI. In all three behavioral tests, vehicle group 
performed significantly worse compared to sham. Ad-TMBIM6 treatment group 
significantly improved sensorimotor coordination as assessed by the fewer number of 
foot faults (Figure 2.5A) and longer distance covered on the rotarod test (Figure 2.5B) 
versus vehicle. In the water maze test, compared to sham group, vehicle group 
demonstrated substantial loss of memory and learning abilities in terms of the time it took 
to reach the platform (Figure 2.5C) as well as the distance travelled to find the platform 
(Figure 2.5D).  
However, Ad-TMBIM6 showed to significantly improve both memory and learning 
function when compared to vehicle (Figure 2.5C-D). Administration of Ad-TMBIM6 
significantly reduced brain atrophy as seen from the percentage of brain weights (Figure 
2.5E). Nissl’s staining demonstrated that Ad-TMBIM6 can attenuate percent brain tissue 
loss (Figure 2.5F).  
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Figure 2.5 Ad-TMBIM6 improved long term neurological deficits when assessed 
at 4 weeks post HI 
Ad-TMBIM6 improved long-term motor deficits as seen from the significantly lower 
number of foot faults (A) and the longer distance traveled on the rotating rod (B) in the 
Ad-TMBIM6 treatment group when compared to vehicle. Long-term learning and memory 
were significantly improved in Ad-TMBIM6 group compared to vehicle (C-D). Percent of 
ipsilateral/contralateral brain weights were significantly improved in Ad-TMBIM6 group 
when compared to vehicle (E). Nissl staining of brains demonstrated a significant lower 
percentage of tissue loss in Ad-TMBIM6 group compared to vehicle (F). (Data expressed 
as mean +/- SD; *p＜0.05 vs sham; #p＜0.05 vs vehicle; n=6-9 using one-way ANOVA 
followed by Tukey multiple-comparison/or Holm-Sidak post hoc analysis). 
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BI-1 siRNA and IRE1α CRISPR Activation Plasmid Reversed Ad-TMBIM6 
Protective Effects at 72h post HI 
To evaluate whether pathway interventions can affect apoptosis and increase infarcted 
area, we used a BI-1 inhibitor (BI-1 siRNA) and a IRE1α activator (IRE1α CRISPR 
Activation Plasmid (AP)). Results demonstrated that Ad-TMBIM6+BI-1siRNA group 
significantly reversed BI-1’s protective effects, as did Ad-TMBIM6+IRE1α CRISPR AP 
group, as seen from the significant increase in infarcted area when compared to Ad-
TMBIM6 only group (Figure 2.6A-B). Both control groups, scramble siRNA and control 
CRISPR AP, did not exacerbate the damage when compared to Ad-TMBIM6 treated 
group. Furthermore, BI-1 siRNA only group (without treatment) further exacerbated the 
injuries when compared to Ad-TMBIM6 treatment group.  
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Figure 2.6 The effects of BI-1 siRNA and IRE1α CRISPR activation plasmid on 
infarct area at 72h Post HI 
The percentage of infarcted area was significantly increased in vehicle, BI-1siRNA and 
IRE1α CRISPR activation group when compared to Ad-TMBIM6 and their respective 
control groups (A-B). Representative schematic for mechanism study (C). (Data expressed 
as mean +/− SD; *p<0.05 vs sham; #p<0.05 vs vehicle; @p<0.05 vs Ad-TMBIM6; 
$p<0.05 vs BI-1 siRNA; +p<0.05 vs Ad-TMBIM6+scramble siRNA; &p<0.05 vs IRE1α 
CRISPR AP; %p<0.05 vs control CRISPR. n=6/group using one-way ANOVA followed 
by Tukey multiple-comparison post hoc analysis).  
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BI-1 Exerted its Neuroprotective Effects via the IRE1α/XBP1/CHOP pathway 
at 72h post HI 
To test the underlying mechanism via which BI-1 attenuated apoptosis the following 
groups were used: sham, vehicle, Ad-TMBIM6, Ad-TMBIM6+BI-1siRNA, Ad-
TMBIM6+scramble siRNA, Ad-TMBIM6+IRE1α CRISPR AP, AD-TMBIM6+ control 
CRISPR, BI-1siRNA only and scramble siRNA only groups. Quantification data 
demonstrated that BI-1 expression levels were significantly increased in the Ad-TMBIM6 
treatment group, Ad-TMBIM6+scramble siRNA and in the Ad-TMBIM6+control 
CRISPR groups; while BI-1 siRNA and IRE1α CRISPR AP groups reversed those effects 
(Figure 2.7A-B). BI-1 siRNA only and scramble siRNA only groups showed similar 
expression levels of BI-1 as vehicle. Ad-TMBIM6 significantly reduced expression of 
pIRE1α, XBP1, CHOP and ROMO1 (a modulator that induces production of ROS); 
while BI-1-siRNA and IRE1α CRISPR AP reversed BI-1’s protective effects which 
demonstrated elevated expression of pro-apoptotic pathway proteins (Figure 2.7A, C-F).  
No significant difference was observed in total IRE1α expression levels 
(quantification data not shown). Immunohistochemistry demonstrated that siRNA 
reduced expression of BI-1 in all three cell types (Figure 2.7G).   
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Figure 2.7 BI-1 exerted its protective effects via the IRE1α/XBP1/CHOP pathway at 
72h post HI 
Representative picture of western blot data (A).  Quantification of bands demonstrated 
that Ad-TMBIM6 as well as control groups (Ad-TMBIM6+scramble siRNA and Ad-
TMBIM6+CRISPR Control) significantly increased BI-1 expression levels in the brain 
when compared to vehicle or sham. While, BI-1 siRNA and IRE1α CRISPR AP 
significantly reversed those effects. Furthermore, BI-1 siRNA only group also reduced BI-
1’s expression levels (B). Data showed that pIRE1α, XBP1, CHOP and ROMO1 
expression levels were significantly elevated in vehicle, BI-1 siRNA and IRE1α CRISPR 
AP groups whereas Ad-TMBIM6 and control groups reversed those effects (C-F) at 72h 
post HI. (Data expressed as mean +/− SD; *p<0.05 vs sham; #p<0.05 vs vehicle; @p<0.05 
vs Ad-TMBIM6; $p<0.05 vs BI-1 siRNA; +p<0.05 vs Ad-TMBIM6+scramble siRNA; 
&p<0.05 vs IRE1α CRISPR AP; %p<0.05 vs control CRISPR; ^p<0.05 vs Ad-TMBIM6+ 
BI-1 siRNA; ε p<0.05 vs BI-1 siRNA only group. n=6/group using one-way ANOVA 
followed by Tukey multiple-comparison post hoc analysis). Immunofluorescent staining 
shows the effects of siRNA on neurons, astrocytes and microglia (G) (Scale bar = 50 μm; 
n=1/group). 
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Overexpression of BI-1 Suppressed Pro-Apoptotic Protein Markers and 
Attenuated Neuronal Apoptosis at 72h post HI 
To evaluate whether over expression of BI-1 with Ad-TMBIM6 could attenuate 
apoptosis, western blot was done to quantify Bcl-2, Bax, Cleaved Caspase 3 (CC3) and 
Caspase 3.The data demonstrated that Ad-TMBIM6 treatment group can significantly 
upregulate anti-apoptotic marker, Bcl-2 (Figure 2.8A-B), while it attenuated expression 
of pro-apoptotic markers, Bax and CC3 (Figure 2.8A, C-D). In addition, administration 
of BI-1 si-RNA and IRE1α CRISPR AP reversed Ad-TMBIM6’s protective effects; it 
significantly upregulated pro-apoptotic markers (Bax and CC3) and downregulated the 
anti-apoptotic marker, Bcl-2 (Figure 2.8A-D). There was no significant difference in total 
Caspase 3 expression levels (quantification data not shown).  
Since HI results in neuronal degeneration and apoptosis, we stained for CC3 and used 
Flouro-Jade C staining to test Ad-TMBIM6’s neuroprotective effects. Immunoflourescent 
staining showed higher expression and co-localization of CC3 on neurons in vehicle 
group compared to sham or Ad-TMBIM6 groups. (Figure 2.8E; Scale bar 100µm). Green 
Flouro-Jade C staining showed  more positively stained neurons undergoing apoptosis in 
vehicle group compared to sham or Ad-TMBIM6 treatment group (Figure 2.8F; Scale bar 
100µm). 
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Figure 2.8 Overexpression of BI-1 attenuated apoptosis at 72h post HI 
Representative picture of western blot data showing bands of the expression levels of Bcl-
2, Bax and CC3 (A). Western blot data quantification of bands showed that Ad-TMBIM6 
significantly increased Bcl-2 expression levels compared to vehicle or sham (B). Ad-
TMBIM6 significantly reduced Bax and CC3 at 72h post HI compared to vehicle while BI-
1 siRNA and IRE1α CRISPR AP intervention groups reversed those effects (C-D). (Data 
expressed as mean +/− SD; *p<0.05 vs sham; #p<0.05 vs vehicle; @p<0.05 vs Ad-
TMBIM6; $p<0.05 vs BI-1 siRNA; +p<0.05 vs Ad-TMBIM6+scramble siRNA; &p<0.05 
vs IRE1α CRISPR AP; %p<0.05 vs control CRISPR. n=6/group using one-way ANOVA 
followed by Tukey multiple-comparison/Holm-Sidak/Dunnett’s post hoc analysis).    
Fluorescent staining showed more positively CC3 stained neurons in vehicle group 
compared to sham or Ad-TMBIM6 treated group (E). (Scale bar 100µm; n=1/group). 
Fluoro-Jade C staining showed more positively stained neurons undergoing apoptosis in 
vehicle group compared to sham or Ad-TMBIM6 treatment group (F). (Scale bar 100µm; 
n=1/group).  
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Discussion 
Understanding cellular and molecular mechanisms can lead to a more effective 
therapies needed to ameliorate the long-term deficits after Hypoxic-Ischemic (HI) injury 
(Volpe 2001; Bracewell et al. , 2002; van Handel et al. , 2007).  Bax Inhibitor-1 (BI-1) is 
a promising target for therapeutic use, however little is known about its signaling 
mechanism which limits its clinical translation. Given the lack of effective treatment 
options for neonatal HI injury, this study focused on identifying a novel role for BI-1 
protein and Endoplasmic Reticulum (ER) stress in the pathophysiology of neonatal HI. 
Hopefully, this new understanding can be leveraged to design interventions that 
positively affect the outcome of HI patients.  
One of the three main pathways triggered after ER stress, main pathology 
encountered post HI injury, is IRE1α; a key molecule responsible for cell fate, as it can 
directly bind to the misfolded proteins, unlike PERK or ATF6 (Gardner et al. , 2011; 
Sano et al. , 2013). Accumulation of unfolded proteins stimulates autophosphorylation of 
IRE1α’s kinase domain, which then activates the RNase to splice X-box-binding protein 
1 (XBP1). This acts as a potent transcription factor that triggers pro-apoptotic signaling 
mechanisms. PERK also contributes to ER stress by attenuating mRNA translation thus 
inhibiting protein synthesis (Sano et al. , 2013). We focused on IRE1α and PERK, as they 
are the major receptors that contribute to ER stress induced cell death.  
BI-1 has been characterized in various insults as a pro-survival protein in ER 
stress (Chae et al. , 2004; Bailly-Maitre et al. , 2006; Lee et al. , 2007; Lisbona et al. , 
2009; Bailly-Maitre et al. , 2010; Castillo et al. , 2011; Robinson et al. , 2011).   BI-1’s 
anti-apoptotic effects were first described in cultured cells and in vivo mice model (Chae 
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et al. , 2004; Bailly-Maitre et al. , 2006; Krajewska et al. , 2011; Ma et al. , 2014). It has 
been reported to directly bind to and inhibit IRE1α (Lisbona et al. , 2009) by abolishing 
its endoribonuclease activity (Castillo et al. , 2011). BI-1’s protective effects were further 
reported in db/db mice where BI-1 protected mice from obesity associated insulin 
resistance due to suppression of IRE1α (Bailly-Maitre et al. , 2010). Some evidence 
showed that BI-1 may also indirectly inhibit PERK signaling pathway (Lee et al. , 2007), 
however, other reports have shown that eIF2α phosphorylation, downstream of PERK, 
was unaltered with BI-1 knockout mice (Bailly-Maitre et al. , 2006). 
BI-1 has been found to be a potent inhibitor of ER stress induced pathways, 
however the exact mechanism via which it may exert its pro-survival signaling remains 
unknown. In this study we investigated the role of BI-1 on ER stress-induced apoptosis, 
and we further elucidated BI-1’s main signaling pathway. As BI-1 has been shown to 
inhibit IRE1α and to some extend PERK (Lee et al. , 2007; Robinson et al. , 2011), we 
sought to investigate their involvement and to identify the dominant factor by using an in 
vitro oxygen glucose deprivation (OGD) model. PC12 cells were transfected with (1) BI-
1 siRNA, IRE1α agonist (APY-29) and antagonist (STF-083010) in combination with 
human adenoviral TMBIM6 (Ad-TMBIM6; gene responsible for expressing BI-1) 
(Bailly-Maitre et al. , 2010) vector to test the role of the IRE1α signaling pathway and (2) 
PERK CRIPSR knockdown and the CCT020312 (PERK agonist) together with Ad-
TMBIM6 to test the involvement of the PERK signaling pathway. Cell viability data 
indicated that Ad-TMBIM6 increased the percentage of viable cells versus cells that 
underwent 3h OGD without Ad-TMBIM6 (Vehicle) (Figure 2.1C-D). Furthermore, BI-1 
siRNA and APY-29 significantly reversed Ad-TMBIM6s protective effects (Figure 
 83 
2.1D). Activation of PERK with CCT020312 decreased the percentage of viable cells 
compared to Ad-TMBIM6. However, double inhibition of PERK with Ad-
TMBIM6+PERK CRISPR yielded a low cell viability count (~40%), which may suggest 
that PERK may not play a major role in BI-1’s protective effects. On the contrary, double 
inhibition of IRE1α with Ad-TMBIM6+STF-083010 improved cell viability to ~85% 
versus ~40% in Vehicle and the PERK CRISPR group (Figure 2.1D). This data indicated 
that manipulation of IRE1α may play a greater role than PERK signaling in BI-1’s 
protective effects.  
In support of our cell viability data, western blot results indicated that Ad-
TMBIM6 or double inhibition of IRE1α with Ad-TMBIM6+ STF-083010, successfully 
upregulated BI-1’s expression levels in PC12 cells and inhibited pIRE1α (Figure 2.2A-
C). However, inhibiting BI-1 with siRNA and activating IRE1α with APY-29, 
significantly reversed those effects as seen from the decreased expression level of BI-1 
(Figure 2.2B). Activation of IRE1α with APY-29 significantly reduced BI-1 and 
increased pIRE1α, however, either activation of PERK with CCT020312 or inhibition 
with PERK CRISPR did not alter BI-1’s nor pIRE1α expression levels (Figure 2.2B-C), 
indicating that BI-1 is more influenced by IRE1α as opposed to PERK. While, APY-29 
significantly increased the pro-apoptotic marker, CC3, CCT020312 did not show 
significant CC3 upregulation (Figure 2.2E). Furthermore, double inhibition of IRE1α 
with Ad-TMBIM6+STF-080310 further reduced CC3 versus double inhibition of PERK 
with Ad-TMBIM6+PERK CRISPR, indicating that BI-1 may more potently attenuate 
apoptosis via inhibition of IRE1α.  
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Summary of our in vitro findings showed that either activating or inhibiting 
PERK did not change BI-1’s expression levels versus Ad-TMBIM6, whereas 
manipulation of the IRE1α receptor showed changes in BI-1. In addition, Ad-TMBIM6 
successfully attenuated pIRE1α expression while inhibition of BI-1 reversed those effects 
(Figure 2.2C). Based on these findings, we can conclude that despite BI-1’s inhibitory 
effects on pPERK expression (Figure 2.2D), the effect isn’t prominent enough to confer 
neuroprotection as seen from the CC3 levels (Figure 2.2E). Taken all the above together, 
we believe that although BI-1 may have some inhibitory effects on PERK, its major 
pathway operates via inhibition of IRE1α signaling.  
We then hypothesized that intracerebroventricular injection of Ad-TMBIM6 
vector would overexpress BI-1 and provide protection in an in vivo neonatal HI model via 
inhibition of IRE1α singling. This hypothesis stems from our in vitro data as well as from 
previous reports on BI-1’s anti-apoptotic effects via inhibition of IRE1α, causing 
disruption of the receptors interaction with downstream pro-apoptotic molecules (XBP1 
and CHOP) (Bailly-Maitre et al. , 2006; Lisbona et al. , 2009; Bailly-Maitre et al. , 
2010). 
Expression of BI-1 may begin within 24-72h of injection, therefore we 
administered Ad-TMBIM6 vector at multiple time points and sacrificed animals at 72h 
post HI to determine the optimal time needed for the virus to replicate and begin 
overexpressing BI-1(Bailly-Maitre et al. , 2010). Our results indicated that administration 
of Ad-TMBIM6 vector at 48h pre-HI significantly reduced the percentage of infarcted 
area at 72h post HI and was chosen as the optimal time (Figure 2.3F). In addition, a low 
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dose viral vector (1.6x1011 PFU) was more protective then the higher dosage (1.7x1011 
PFU) (Figure 2.3G).  
To evaluate whether Ad-TMBIM6 attenuated neuronal apoptosis we performed 
Flouro-Jade C (FJC) staining, which stains for degenerating neurons (Figure 2.8F). Ad-
TMBIM6 vector reduced the number of FJC positively stained neurons, indicating 
attenuation of apoptosis. To further confirm BI-1’s anti-apoptotic effects, we stained for 
CC3 on neurons and saw that Ad-TMBIM6 was able to attenuate the expression of CC3 
as well as reduce co-localization with neurons which is indicative of less neuronal death 
(Figure 2.8E).  
To determine a delay in acquisition of neurobehavioral milestones and the effects 
of Ad-TMBIM6 treatment post HI, neurocognitive outcomes were measured at 4 
weeks using the Morris water maze, rotarod and foot fault tests. Results showed that Ad-
TMBIM6 significantly improved motor and learning deficits (Figure 2.5A-D). 
Furthermore, brain weight measurement and Nissl staining showed a significantly lower 
percentage of tissue loss in the Ad-TMBIM6 group compared to vehicle (Figure 2.5E-F), 
which is representative of our behavior findings.  
Finally, to determine that BI-1 confers protection via inhibition of IRE1α, we 
used a BI-1 siRNA to inhibit BI-1 and an IRE1α CRISPR activation plasmid (AP) to 
counteract BI-1’s effects as depicted in the schematic in figure 2.6C. From our WB 
results, we demonstrated that inhibition of BI-1 with siRNA, or activation of IRE1α with 
CRISPR AP, significantly reduced BI-1’s expression levels (Figure 2.7A-B) and 
increased pro-apoptotic markers (Figure 2.8 C-D). On the contrary, administration of Ad-
TMBIM6 significantly increased BI-1 levels in the brain, attenuated pIRE1α, XBP1 
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CHOP and reduced pro-apoptotic markers via inhibition of IRE1α (Figure 2.7 and 2.8). 
To determine siRNA’s effects on different cell types we stained for neurons, astrocytes 
and microglia. Results demonstrated a reduction in BI-1 expression in all three cell types 
after administration of siRNA (Figure 2.7G) versus Ad-TMBIM6 treated groups (Figure 
2.4A, C).  
The ER dictates the fate of proteins, while the level of redox mediators modulates 
the level of reactive oxygen species (ROS) (Cao et al. , 2014; Zeeshan et al. , 2016). 
Persistent ER stress causes accumulation of misfolded proteins, which then triggers 
IRE1α activation and further upregulation of CHOP. Increased levels of CHOP further 
exacerbate cell death signaling through oxidative stress, which also contributes to ROS 
generation (Cao et al. , 2014; Zeeshan et al. , 2016). Herein, we used a ROS marker, 
Reactive-Oxygen-Species-Modulator-1 (ROMO1), which is protein coding gene 
responsible for increasing ROS in cells. Western blot data demonstrated a significant 
reduction in ROMO1 levels in the brain after Ad-TMBIM6 (Figure 2.7F).  These results 
were confirmed to be via BI-,1 as either BI-1 inhibition with siRNA, or over activation of 
IRE1α with CRISPR AP in the presence of Ad-TMBIM6, reversed those effects.  
In summary, overexpression of BI-1 attenuated apoptosis and improved 
neurological outcomes post HI. The main novelty lies in successfully identifying BI-1’s 
protective role and signaling pathway in ER stress induced apoptosis post neonatal HI. 
This work is essential as it provides critical information that may be used to develop 
more beneficial clinical treatments for HI patients, as well as provide a foundation for 
future research in other diseases with similar pathologies.    
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Abstract 
 Oxidative stress, inflammation and Endoplasmic Reticulum (ER) stress play a 
major role in the pathogenesis of hypoxic ischemic (HI) injury in the neonate. ER stress 
results in accumulation of unfolded proteins that trigger the NADPH-P450 reductase 
(NPR) and the microsomal monooxygenase system which is composed of cytochrome 
P450 members (CYP) generating reactive oxygen species (ROS) as well as the release of 
inflammatory cytokines.  
 We explored the role of Bax Inhibitor-1 (BI-1) protein encoded by the 
Transmembrane Bax inhibitor Motif Containing 6 (TMBIM6) gene, in protection from 
ER stress after HI brain injury. BI-1 may regulate ER stress induced ROS production and 
release of inflammatory mediators via two main mechanisms. Firstly, BI-1 can directly 
bind to NPR, thus disrupting the NPR-CYP complex; and secondly, ROS production is 
also controlled by the redox sensitive transcription factor, Nrf-2, which controls 
expression of different anti-oxidant enzymes such as HO-1. BI-1 can upregulate Nrf-2, 
promoting an increase in anti-oxidant enzymes, thus reducing ROS. Therefore, in this 
study we evaluated BI-1’s inhibitory effects on ROS and inflammation by overexpressing 
BI-1 in 10-day old unsexed Sprague-Dawley rat pups that underwent right carotid 
ligation, followed by 1.5h of hypoxia using adenoviral mediated gene delivery of 
TMBIM6.  
 Overexpression of BI-1 significantly reduced the percentage of infarcted area; 
while silencing BI-1 reversed those effects. BI-1’s mediated protection was observed to 
be via inhibition of P4502E1, a major contributor to ROS generation, as seen from the 
decreased levels of P4502E1 and upregulation of Nrf-2 and HO-1, which correlated with 
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a decrease in ROS and inflammatory markers. This effect was reversed with BI-1 or Nrf-
2 silencing. This study showed a novel role for BI-1 to inhibit a major regulator of ROS 
production.  Inhibition of P4502E1, together with activation of Nrf-2, demonstrates that 
BI-1 has a great promise as a therapeutic target.   
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Introduction 
Hypoxia Ischemia (HI) in the perinatal period is associated with long-term 
disabilities in children affecting 1-4 infants per 1000 births (Vannucci 2000). The most 
common cause of HI is intrauterine asphyxia, which may be brought on by several factors 
such as placental artery clotting, abruption or inflammatory processes (Fatemi et al. , 
2009). These result in diminished supply of blood and oxygen to the neonatal brain. In 
the event of prolonged abruption and extended period of HI the neonate develops hypoxic 
ischemic encephalopathy (HIE), causing irreversible brain injury (Fatemi et al. , 2009). 
Despite the significant research progress identifying many molecular mechanisms for 
neonatal HIE, therapeutic interventions are limited (Ferriero 2004; Gunn et al. , 2008; 
Shankaran 2008).  
One of the main contributing injury mechanism post HI is the disruption of 
correct protein folding, that subsequently triggers reactive oxygen species (ROS) 
accumulation, followed by activation of microglia, ultimately causing inflammation 
(Ferriero 2004; Khwaja et al. , 2008). Inflammatory cytokine release has been associated 
with HIE and has been shown to be significantly elevated in the full-term infant, which is 
linked with further exacerbating the damage and results in poor neurodevelopmental 
outcome (Fatemi et al. , 2009).  Therefore, inhibition of inflammation post HI is an 
attractive target for new therapeutic strategies.   
Correct folding of transmembrane proteins takes place in the endoplasmic 
reticulum (ER) which is composed of an elaborate system of chaperones and enzymes to 
aid in this process(Stahl et al. , 2013). However, under stressful conditions, such as after 
a hypoxic ischemic event, the number of proteins to be folded exceeds the capacity of the 
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chaperones, leading to an accumulation of unfolded proteins, causing ER stress (Sano et 
al. , 2013). The ER responds to this by activating the unfolded protein response (UPR), 
which activates sensor proteins which recognize and ameliorate ER stress (Xu et al. , 
2005; Sano et al. , 2013; Zhang et al. , 2014). However, persisting ER stress leads to the 
overactivation of the UPR, a highly redox dependent pathway, which is followed by an 
accumulation of reactive oxygen species (ROS) (Kim et al. , 2009). ROS are a natural 
byproduct of signaling pathways, however during stress, ROS production is increased 
significantly, which causes oxidative stress and damage to the cell (Kim et al. , 2009).   
A major source of ROS production at the ER is from the microsomal 
monooxygenase (MMO) system which is composed of cytochrome P450 (CYP), 
NADPH-P450 reductase (NPR) and some phospholipids (Kim et al. , 2009; Henke et al. , 
2011; Robinson et al. , 2011). Specifically, cytochrome P4502E1, a member of 
cytochrome P450, is associated with the production of large amounts of ROS. This has 
been shown to occur during leakage of electron transfer between P4502E1 and NPR, 
thus, indicating an important role of these cytochromes during ER stress (Kim et al. , 
2009; Robinson et al. , 2011).  
BI-1 has been shown to regulate ER stress induced ROS production via two 
important mechanisms (Li et al. , 2014). Firstly, BI-1 can directly inhibit ROS production 
by disrupting the NPR-CYP complex, which is a major contributor to ROS generation. 
BI-1 causes dissociation of the complex by altering the electron flow from P4502E1 to 
NPR, causing destabilization of this complex, blocking electron transfer and attenuating 
ROS accumulation (Lee et al. , 2007; Kim et al. , 2009; Henke et al. , 2011). The 
P4502E1 member was found to be significantly reduced and its upregulation attenuated 
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after ER stress in BI-1 overexpressing cells (Kim et al. , 2009). Secondly, BI-1 can 
directly increase the production of anti-oxidant factors such as nuclear factor erythroid 2-
related factor 2 (Nrf-2), a transcription factor the regulates ROS production (Lee et al. , 
2007; Li et al. , 2014). It does so by stimulating the production of the anti-oxidant 
enzyme, heme oxygenase-1 (HO-1), which in turn blocks ROS, thereby attenuating 
inflammation and promoting cell survival. G. H. Lee showed that cells overexpressing 
BI-1 increased Nrf-2 activation and HO-1 expression thus blocking ROS. BI-1’s 
protective effects against ER stress induced cell death were abrogated after inhibition of 
HO-1 (Lee et al. , 2007).    
The specific objective of this study was to establish that overexpression of BI-1 
protein, with Adenoviral-TMBIM6 vector, can attenuate the morphological and 
neurological consequences post neonatal HI via attenuation of ER stress induced ROS 
production and inflammation. We hypothesized that BI-1 will reduce ER stress induced 
ROS accumulation and subsequent inflammation via coupling with NPR and hence 
disrupting the NPR-CYP complex. In addition, BI-1 can upregulate Nrf-2 which leads to 
an increase in HO-1 production. HO-1 is a rate-limiting enzyme shown to be able to 
attenuate ROS accumulation. Increased levels of HO-1 may limit oxidative dysregulation 
which causes misfolding of ER proteins thereby decreasing the unfolded protein response 
(UPR). 
With this study we hope to establish a novel role for BI-1 protein in regulating ER 
stress induced ROS production after neonatal HI.  
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Materials and Methods 
In vivo Experiments 
All protocols are approved by The Institutional Animal Care and Use Committee of 
Loma Linda University and with NIH guide for The Care and Use of Laboratory 
Animals. The animals were cared for and all studies conducted in accordance with the 
United States Public Health Service's Policy on Humane Care and Use of Laboratory 
Animals. Sprague Dawley rat mothers, with litters of 10~12 pups, were purchased from 
Harlan Labs (Livermore, CA). The pups were kept in temperature-controlled 
environment with regular light/dark cycle until they were ready for surgery at 10days old 
post birth (P10), to allow them enough time to adjust.  
A total of 100 unsexed rat pups weighing 15-20g were assigned to the following 
groups: sham, HI+Vehicle, HI+Ad-TMBIM6, HI+Ad-TMBIM6+BI-1siRNA, HI+Ad-
TMBIM6+Nrf-2siRNA, HI+Ad-TMBIM6+scramble siRNA, HI+BI-1siRNA, HI+Nrf-
2siRNA and HI+scramble siRNA.  
 
Hypoxic Ischemic Rat Model 
Hypoxic Ischemic (HI) injury was induced as previously described following the 
well-established Rice Vannucci model (Vannucci et al. , 1997; Vannucci et al. , 2004). 
Briefly, P10 unsexed rats were anesthetized with 3% isoflurane gas in air and maintained 
at 2.5% isoflurane during surgery.  Once the rat was fully anesthetized and unresponsive, 
the rats neck was prepared and draped using standard sterile techniques.  A small midline 
neck incision on the anterior neck was made with a No. 11 blade surgical knife 
(approximately 3-5 mm in length).  The right carotid artery was dissected and isolated 
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from surrounding structures.  The carotid artery was then double ligated with 5-O 
surgical suture and cut between the ligations.  Animal’s skin was sutured back to close 
the incision. Throughout the surgical and postoperative period, temperature was 
controlled with heating blankets and incubators.  Rats were then allowed to recover for 
1h on a heated blanket, then placed in a 2L Erlenmeyer airtight flask, which was partially 
submerged in a 37 °C water bath to maintain a constant thermal environment.  Rat pups 
were exposed to a gas mixture of 8% Oxygen and 92% Nitrogen for 90min. Thereafter, 
the animals were returned to their mothers and monitored daily.  
 
Time Course Evaluation of Proteins 
Time course expression of endogenous BI-1, P4502E1, NPR, pNrf-2 and HO-1 
levels were measured at 6h, 12h, 24h and 72h post HI. Rats were randomly divided into 
the groups and brains were collected for western blotting. Sham animals underwent 
surgery; however, the artery was only isolated without being ligated or cut, and pups were 
euthanized at 24h post HI. 
 
Viral Administration 
Human adenoviral-TMBIM6 vector (Ad-TMBIM6) (Vector Biolabs) was injected 
intracerebroventricularly (icv) at 2µl containing 1.6x1011 PFU/ml per injection (Bailly-
Maitre et al. , 2010) at 48h pre-HI. The best dose and time of injection of virus was 
determined in our preliminary experiments (data not shown).  
 
 
 102 
RNAi Administration 
Rats were anesthetized and placed on a stereotactic frame. 2µl of BI-1 siRNA 
(300pmol/µl, Sigma-Aldrich), Nrf-2 siRNA or scramble siRNA (300pmol/µl, Santa Cruz) 
were administered icv using a Hamilton syringe (10µl, Hamilton Co) into the right lateral 
ventricle (1.5mm posterior, 1.5mm lateral to bregma and 1.7mm down from surface of 
brain) at 48h pre-HI at a rate of 0.3µl/min (Shi et al. , 2017). To prevent backflow, needle 
was left in place for 10min after administration was completed and was then withdrawn 
slowly over 5min. The hole was sealed with bone wax and the skin was sutured.  
 
Infarct Area Measurements  
TTC (2,3,5-Triphenyltetrazolium Chloride Monohydrate) staining was performed 
at 72h post HI to determine percentage of infarcted area. Animals were anesthetized, the 
brains were removed and sectioned into 2mm slices. A total of 5-6 slices were cut per 
brain and were then immersed in 2% TTC solution until brains turned pink-red (~5min) 
at room temperature (Zhou et al. , 2009; Li et al. , 2012). Slices were then washed in PBS 
and fixed overnight in 10% formaldehyde solution and imaged.  Red stained tissue 
indicated live tissue while white indicated the infarcted tissue. Image J software was used 
to calculate the percentage of infarcted area.  
The area of each slice was calculated using the formula: ((Area of Contralateral 
Hemisphere – Area of non-infarcted ipsilateral hemisphere) / 2* (Area of Contralateral 
Hemisphere)) * 100 (Chen et al. , 2018; Xu et al. , 2018). The average of all 5 slices was 
taken as a representative of percentage of infarcted area for each animal. All experiments 
were performed in an unbiased blinded fashion. 
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Western Blotting for Brain Tissue 
Western blotting was performed as previously described (Li et al. , 2015; Shi et 
al. , 2017; Xie et al. , 2017). Rats were anesthetized at 72h post HI and transcardially 
perfused with 100ml ice cold PBS (pH 7.4). The brain was isolated and divided into 
contralateral and ipsilateral hemispheres, then immediately snap frozen in liquid nitrogen 
and stored in -80°C for further use. To prepare samples for western blotting, the 
ipsilateral hemispheres were homogenized in RIPA lysis buffer (Santa Cruz 
Biotechnology) for 15min followed by centrifugation at 14,000g at 4°C for 30min. The 
supernatant was collected, and protein concentration was measured using a detergent 
compatibility assay (Catalog number: 5000112, DC™ Protein Assay Kit II, Bio-Rad, 
USA).  
Equal amounts of protein (30μg, chosen as best loading amount based on previous 
studies (Thacker et al. , 2016; Moritz 2017; Shi et al. , 2017) were loaded on an 8%~12% 
SDS-PAGE gel and electrophoresed and then transferred to a nitrocellulose membrane 
(0.2μm). The membrane was blocked for 1h and then incubated with primary antibodies 
overnight at 4°C: BI-1 antibody (1:1000, Abcam), anti-P4502E1 (1:2500, Abcam), Anti-
NPR antibody (1:1000, Abcam), anti-pNrf-2/Nrf-2 antibody (1:1000, Abcam), anti-HO1 
antibody (1:200, Santa Cruz Biotechnology), anti-ROMO1 antibody (1:1000, Abcam), 
anti-TNFα antibody (1:1000, Abcam), anti-IL-6 antibody (1:500, Abcam), anti-Il-1β 
antibody (1:500, Abcam), Anti-HA tag antibody (1:4000, Abcam) and actin (1:4000, 
Santa Cruz Biotechnology). The following day, membranes were incubated at room 
temperature for 1h with horseradish peroxidase-conjugated secondary antibodies (Santa 
Cruz Biotechnology) followed by chemiluminescence detection (ECL plus kit, 
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Amersham Bioscience). The densitometric quantification of the bands was performed 
with image J software and results were expressed as relative density to actin.   
 
Histology 
Brains were post-fixed in formalin, and then sectioned into 10μm thick coronal 
slices by cryostat (CM3050S; Leica Microsystems) for immunohistochemistry and 
Dihydroethidium (DHE) staining.   
Immunofluorescence staining: Rats were anesthetized at 72h post HI and 
transcardially perfused with PBS and 10% formalin. Brain sections were then post fixated 
with formalin overnight and dehydrated in 30% sucrose solution for 3-5d after which 
brains were frozen in OCT. Immunofluorescence staining was performed as previously 
described (Shi et al. , 2017). The tissue mounted on the slides was washed with 0.1M 
PBS three times for 5min and then incubated in 0.3% Triton X-100 in 0.1M PBS for 
30min at room temperature. The tissue was then washed once more by 0.1M PBS for 
5min, 3 times, and primary antibodies were applied overnight at 4°C: anti-BI-1 antibody 
(1:100, Abcam), anti-P4502E1 antibody (1:100, Abcam), anti-NPR (1:100, Abcam), anti-
Nrf-2 (1:100, Abcam), anti-HA tag (1:50, Abcam), anti-Iba-1 (1:100, Abcam), anti-Il-1β 
(1:100, Abcam) and anti-MPO (1:100, Abcam). After washing with PBS, sections were 
incubated with appropriate secondary antibodies: anti-rabbit IgG-TR, anti-mouse IgG-
FITC, anti-goat IgG-FITC, anti-rabbit IgG-FITC (1:200) for 2h @ RT. Finally, slides 
were mounted using Vectashield Antifade with DAPI (Catalog Number: H-1200, Vector 
Laboratories Inc., USA) and visualized under Fluorescent microscope (Leica DMi8, 
Leica Microsystems) and Magna Fire SP system (Olympus) was used to analyze 
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microphotographs. Quantification of Il-1β and MPO positive cells was manually counted 
in the peri-ischemic regions. A total of 6 sections/brain were averaged and expressed as 
the ratio of positive cells to total cells (%).   
DHE staining: To evaluate ROS production we stained brain slices with 
Dihydroethidium (DHE) stain (Owusu-Ansah et al. , 2008). Slides were prepared as 
described above in Immunofluorescence staining methods. To prepare a stock solution, a 
total of 25g of Dihydroethidium (DHE) (Invitrogen) solid was diluted with 1ml methanol. 
The working reagent was prepared by taking 25.3µl of stock solution and diluting it in 
1ml methanol. After washing slides in PBS 1x10min, a working reagent of DHE was 
applied to each brain section and slides were let stand in a dark room for 30min. Slides 
were then washed in PBS 3x10min, dried off, then mounted using DAPI and coverslip. A 
Leica DMi8 fluorescent microscope was used to visualize the slides.   
 
In Vitro Experiments 
Rat microglial immortalized cell line, HAPI (Millipore Sigma), was used at passage 6 
through 9.  Cells were grown as previously described (Dickson et al. , 1986). 
 
Oxygen Glucose Deprivation Model 
Cells were grown in full growth media which was replaced with glucose deprived 
media prior to being placed in a chamber. Cells were placed in a hypoxic chamber and 
flushed with 1% Oxygen for 3h. Exposure of cells to 3h of OGD was chosen to be best 
time from our preliminary results (data not shown). Media was removed, and complete 
growth media was re-introduced to the cells. Cells were left in an incubator to recover for 
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18h, after which, they were prepared for cell death assay and western blotting (Agani et 
al. , 2002; Souvenir et al. , 2014).  
 
Cell Death Assay 
To determine the percentage of viable cells, we used trypan exclusion as 
previously described (Souvenir et al. , 2014). Briefly, cells were scraped from the plates, 
centrifuged for 5min, and then re-suspended in 10ml complete growth media. Equal 
volumes of cell suspension were added to Trypan blue, cells were then vortexed and let 
stand for 3min. 10µl from mixture was placed on cell counter slides and slides were read 
using an automated cell counter using the average of 6 counts (Souvenir et al. , 2011).  
 
Western Blotting for Cells 
Cells were collected 18h after OGD and stored for western blotting as previously 
described (Dominguez et al. , 2008; Souvenir et al. , 2014). Briefly, cells were scraped, 
centrifuged and then re-suspended in 1ml PBS, after which they were centrifuged one 
more time at 14000rpm for 5min. The remaining supernatant was removed after 
centrifugation, leaving only the pellet. RIPA lysis buffer was added with protease 
inhibitor cocktail and pipetted thoroughly until the pellet was fully dissolved. This 
suspension was then left on ice for 20min following which it was centrifuged for 30min. 
The supernatant was harvested while pellet was discarded. Protein concentration was 
measured using Bradford assay and SD-PAGE electrophoresis was performed as 
previously described (Dominguez et al. , 2008). Primary antibodies: BI-1 antibody 
(1:200, Abcam), anti-P4502E1 antibody (1:1000, Abcam), anti-Nrf-2 antibody (1:1000, 
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Abcam), anti-TNFα antibody (1:1000, Abcam), anti-IL-6 antibody (1:500, Abcam), anti-
Il-1β antibody (1:500, Abcam) and actin (1-4000, Santa Cruz) were applied to the 
membrane and left overnight.  
 
Calculation of MOI 
  The Multiplicity of Infection (MOI) was calculated to determine the total amount 
of infectious particles needed to infect one cell. MOI was calculated as follows: #cells * 
desired MOI= total PFU (or Plaque Forming Units) needed; (total PFU needed) / 
(PFU/ml) = total ml of virus needed to reach your desired dose. A 100MOI of Ad-
TMBIM6 virus was chosen as the optimal amount needed to infect cells and provide 
protection from our preliminary results (data not shown). 
 
siRNA Transfection 
Cells were allowed to differentiate and reach 80% confluency in poly D-lysine coated 
6 well plates prior to transfection. Both BI-1 and Nrf-2 siRNAs were prepared according 
to manufacturer’s protocol (Sigma-Aldrich); A stock solution of 10µM siRNA was 
prepared. From the siRNA stock,4µl was taken and mixed with 125µl Opti-MEM. In a 
separate tube, 7µl liofectamine3000 was mixed with 125µl Opti-MEM. The solution from 
both tubes was combined, mixed well, and left to sit at room temperature for 15-45min. 
Growth media was removed from cells and replaced with 250µl/well siRNA transfection 
solution as prepared above. An additional 1ml Opti-MEM was added to each well and 
cells were then placed in an incubator for 5-7h, following which, the media was removed 
and replaced with normal growth media.   
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Statistical Analysis 
  Statistical analysis was performed using one-way analysis of variances (ANOVA), 
followed by Tukey test.  All values were presented as mean ± standard deviation (SD), 
with a P-value less than 5% considered significant. Sample sizes were determined by 
power of 0.8, α=0.05, and a 20% standard deviation from the preliminary results. The 
estimated sample size was 6-8/group for in vivo studies and 4/group for cell culture 
studies. All rats were randomly assigned to each group and all investigators were blinded.  
 
Results 
Time Course Expression of Endogenous Proteins post HI 
Endogenous expression of BI-1, NPR, P4502E1, pNrf-2 and HO-1 were measured at 
6h, 12h, 24h and 72h post HI.  BI-1 levels significantly increased at 24h post HI and 
returned to sham levels at 72h post HI (Figure 3.1A-B). While NPR expression levels 
showed no changes (Figure 3.1B), P4502E1 significantly increased in a time dependent 
manner, reaching peak at 72h post HI (Figure 3.1C). Nrf-2 levels significantly decreased 
from 6h to 72h, reaching significantly lower expression levels at 72h post HI compared to 
sham (Figure 3.1D). Lastly, HO-1 showed to peak at 24h post HI (Figure 3.1E).  
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Figure 3.1 Endogenous Expression levels of BI-1, NPR, P4502E1, Nrf-2 and HO-1 
post HI  
Representative pictures of Western blot bands (A). BI-1 expression levels significantly 
increased in a time-dependent manner from 6h to 24h and returned to sham levels at 72h 
post HI (B). There were no changes in endogenous NPR levels among the groups (C). The 
expression of P4502E1  increased at 6h and remained elevated, reaching significance at 
72h post HI (D). Nrf-2 levels decreased in a time-dependent manner (E). HO-1 levels 
increased at 24h and 72h post HI (Data expressed as mean +/- SD; *p<0.05 vs sham; # p
＜0.05 vs 6h, @ p < 0.05 vs 24h; n=4, using one-way ANOVA followed by Tukey multiple-
comparison post hoc analysis). 
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To Determine Amount of Ad-TMBIM6 Viral Vector Present in the Brain and 
its Effects on Infarction at 72h post HI 
To determine amount of Ad-TMBIM6 present in the brain at 72h post HI, western 
blot was performed using anti-HA tag antibody. This specifically measures how much 
virus was in the brain when administered 48h pre-HI. Quantification data showed that 
there was significant amount of Ad-TMBIM6 present at 72h post HI versus nothing in 
sham or vehicle. To further confirm these findings, IHC staining results indicated a large 
expression of Ad-TMBIM6 in the brain when stained with anti-HA tagged antibody 
(Figure 3.2A). There was no staining seen for Ad-TMBIM6 in sham or vehicle (data not 
shown). 
To evaluate the effects of pathway interventions on the percentage of infarcted area, 
we used a BI-1 inhibitor (BI-1 siRNA) and a Nrf-2 inhibitor (Nrf-2 siRNA). Results 
showed that Ad-TMBIM6+BI-1siRNA significantly reversed BI-1’s protective effects as 
did Ad-TMBIM6+Nrf-2siRNA group. This is seen from the significant increase in 
percent infarcted area when compared to Ad-TMBIM6 only group (Figure 3.2B). Control 
group, Ad-TMBIM6+scramble siRNA, did not exacerbate the damage when compared to 
Ad-TMBIM6 treated group. Furthermore, BI-1 and Nrf-2 siRNA only groups (without 
treatment) showed similar percent infarcted area as compared to HI+vehicle or 
HI+scramble siRNA groups. 
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Figure 3.2 Inhibition of BI-1 or Nrf-2 increased percent infarcted area at 72h Post HI 
Anti-HA tagged antibody was used to measure amount of viral vector present in the brain 
at 72h post HI. Western blot data indicated a significant expression of Ad-TMBIM6 in the 
brain after intracerebroventricular administration (A) Percent infarct area was significantly 
increased in vehicle, BI-1siRNA and Nrf-2 siRNA groups when compared to Ad-TMBIM6 
and the respective control group (B). (Data expressed as mean +/− SD; *p<0.05 vs sham; 
#p<0.05 vs vehicle; @p<0.05 vs Ad-TMBIM6 or scramble; n=6-8/group using one-way 
ANOVA followed by Tukey multiple-comparison post hoc analysis). 
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Overexpression of BI-1 Disrupted the NPR-CYP Complex at 72h post HI 
To determine BI-1’s role on the NPR-CYP complex the following groups were used: 
sham, vehicle, Ad-TMBIM6, Ad-TMBIM6+BI-1siRNA, Ad-TMBIM6+Nrf-2 siRNA, 
Ad-TMBIM6+scramble siRNA, HI+BI-1siRNA only, HI+Nrf-2siRNA only and 
HI+scramble siRNA only groups.  
Quantification data showed that BI-1 expression levels were significantly increased in 
the Ad-TMBIM6 treatment and in the Ad-TMBIM6+scramble siRNA groups, while BI-1 
siRNA reversed those effects (Figure 3.3A-B). In addition, all three groups (without Ad-
TMBIM6) BI-1 siRNA, Nrf-2 siRNA and scramble, showed low expression levels of BI-
1 versus Ad-TMBIM6.  
Ad-TMBIM6 significantly reduced expression of P4502E1 (Figure 3.3C), while 
silencing BI-1 reversed those effects, as seen from the elevated expression levels of 
P4502E1 (Figure 3.3C). 
To observe changes in BI-1 and P4502E1 expression levels, as well as co-localization 
with microglia, after either Ad-TMBIM6 or after silencing of BI-1 and Nrf-2, 
immunofluorescence staining was performed. Data showed increased expression of BI-1 
and colocalization on microglia in Ad-TMBIM6 treatment group and scramble control 
group compared to sham or vehicle while BI-1 siRNA reversed those effects (Figure 
3.3D). On the contrary, P4502E1 expression levels were elevated in vehicle, BI-1 siRNA 
and Nrf-2 siRNA groups but not in sham or Ad-TMBIM6 treated groups (Figure 3.3E). 
There was also col-localization of P4502E1 on microglia. 
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Figure 3.3 The effects of BI-1 inhibition on the NPR-CYP complex at 72h post HI 
Representative picture of western blot data (A).  Quantification of bands showed that Ad-
TMBIM6 as well as control group (Ad-TMBIM6+scramble siRNA) significantly increased 
BI-1 expression levels in the brain when compared to vehicle or sham, while, BI-1 siRNA 
and Nrf-2 siRNA significantly reversed those effects. Furthermore, BI-1 and Nrf-2 siRNA 
only groups also reduced BI-1’s expression levels (B). Data showed that P4502E1 
expression levels were significantly elevated in vehicle and BI-1 siRNA groups whereas 
Ad-TMBIM6 and control group reversed those effects (C) at 72h post HI. (Data expressed 
as mean +/− SD; *p<0.05 vs sham; #p<0.05 vs vehicle; @p<0.05 vs Ad-TMBIM6 or 
scramble; n=6/group using one-way ANOVA followed by Tukey multiple-comparison post 
hoc analysis).  
Immunofluorescence staining showed a significantly higher expression of BI-1 on 
microglia in Ad-TMBIM6 treatment and scramble groups compared to sham or vehicle, 
while BI-1 siRNA reversed those effects (D). Staining showed higher expression and co-
localization of P4502E1 on microglia in vehicle, BI-1 siRNA and Nrf-2 siRNA groups 
compared to sham or Ad-TMBIM6 treated groups (E). (Green was for microglial staining, 
Red was for BI-1/ or P4502E1 staining and Blue was for DAPI). Merge showed the 
colocalization of BI-1 or P4502E1 on microglia (D-E). (Scale bar = 50 μm; n=3/group). 
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BI-1 Upregulated pNrf-2 Expression and Induced Anti-Oxidant Enzyme 
Production at 72h post HI 
To evaluate overexpression of BI-1 on Nrf-2 levels and its ability to upregulate anti-
oxidant enzymes needed to block ROS, the following groups were employed: sham, 
vehicle, Ad-TMBIM6, Ad-TMBIM6+BI-1siRNA, Ad-TMBIM6+Nrf-2 siRNA, Ad-
TMBIM6+scramble siRNA, HI+BI-1siRNA only, HI+Nrf-2siRNA only and HI+scramble 
siRNA only groups. Quantification data of western blot bands indicated a significantly 
higher expression of pNrf-2 in Ad-TMBIM6 treated groups when compared to vehicle. 
Either silencing BI-1 or Nrf-2 with siRNAs reversed those effects (Figure 3.4A, C). An 
increase in Nrf-2 levels was followed by an increase in the anti-oxidant enzyme HO-1 in 
the Ad-TMBIM6 group when compared to vehicle (Figure 3.4A, D). Furthermore, 
inhibition of BI-1 or Nrf-2 significantly decreased HO-1 levels and its ability to block 
ROS. 
In addition, to look at expressions of NPR and Nrf-2 and co-localization with 
microglia in the presence of Ad-TMBIM6 as well as with BI-1 and Nrf-2 inhibition, we 
performed immunohistochemical staining. Fluorescent staining showed that although 
NPR co-localized with microglia, its expression levels were unchanged among groups 
(Figure 3.4E).  On the contrary, Ad-TMBIM6 increased Nrf-2 expression and co-
localization with microglia compared to sham or vehicle, while Nrf-2 siRNA abolished 
that effect (Figure 3.4F). 
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Figure 3.4 BI-1’s role in the Nrf-2 signaling pathway at 72h post HI  
Representative picture of western blot data (A).  No changes were observed in NPR 
expression levels among groups (B) Quantification of bands showed that Ad-TMBIM6 as 
well as control group (Ad-TMBIM6+scramble siRNA) significantly upregulated pNrf-2 
levels versus vehicle, BI-1 siRNA and Nrf-2 siRNA groups (C) Ad-TMBIM6 significantly 
upregulated HO-1 expression levels while BI-1 siRNA and Nrf-2 siRNA reversed those 
effects (D). (Data expressed as mean +/− SD; *p<0.05 vs sham; #p<0.05 vs vehicle; 
@p<0.05 vs Ad-TMBIM6 or scramble; n=6/group using one-way ANOVA followed by 
Tukey multiple-comparison post hoc analysis). 
Immunofluorescence staining showed minimal changes in NPR expression among groups 
(E) while Nrf-2 levels were upregulated in Ad-TMBIM6. Those effects were abolished in 
the Nrf-2 siRNA group (F). (Green was for microglial staining, Red was for NPR / or Nrf-
2 staining and Blue was for DAPI. Merge showed the colocalization of NPR or Nrf-2 on 
microglia (E-F). (Scale bar = 50μm; n=3/group). 
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BI-1 Overexpression Attenuated ROS Production and Inflammation at 
72h Post HI 
To evaluate whether over expression of BI-1 with Ad-TMBIM6 could inhibit 
ROS production and subsequently attenuate inflammation, western blot was done to 
quantify ROMO1 (a modulator that induces production of ROS), IL-6, TNFα and IL-1β 
expression levels. Data showed that Ad-TMBIM6 treatment group significantly reduced 
ROMO1 levels (Figure 3.5A-B) and attenuated pro-inflammatory markers, IL-6, TNFα 
and IL-1β (Figure 3.5C-E). In addition, administration of BI-1 siRNA and Nrf-2 siRNA 
reversed Ad-TMBIM6’s protective effects as seen from the significantly higher 
upregulation of pro-inflammatory mediators and ROS.  
Since HI results in induction of inflammation, we stained for IL-1β (a pro-
apoptotic marker) with microglia. The counting of positively stained cells for IL-1β with 
microglia showed a higher percentage of IL-1β on microglia in vehicle, BI-1 siRNA and 
Nrf-2 siRNA groups compared to sham,  Ad-TMBIM6 or scramble group.  (Figure 3.5F; 
Scale bar 50µm). 
To evaluate ROS production, we stained brain slices with Dihydroethidium 
(DHE) dye. Cells with high ROS accumulation will have a red fluorescent light. Our data 
revealed a higher number of red positively stained cells in vehicle and siRNA groups 
versus sham, Ad-TMBIM6 and control group in cortex region (Figure 3.6A).  
Furthermore, we also stained for ROS around the ventricles and observed trends 
similar to the cortex region (Figure 3.6B). In addition, to determine whether ROS 
accumulation is correlated with increased inflammation we stained for Myeloperoxidase 
(MPO; a marker that shows the inflammatory activity) and detected significantly higher 
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expression of MPO positively stained cells in vehicle and siRNA groups compared to 
sham or Ad-TMBIM6 treated group (Figure 3.6C).Thus showing both a correlation 
between an increase in ROS production with an increase in inflammation, as well as BI-
1’s ability to inhibit ROS production and the increase in inflammation independently.  
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Figure 3.5 Overexpression of BI-1 attenuated ROS production and inflammation at 
72h post HI  
Representative picture of western blot data showing bands of the expression levels 
of ROMO1, IL-6, TNFα and IL-1β (A). Western blot data quantification of bands showed 
that Ad-TMBIM6 significantly reduced ROMO1 (B), IL-6 (C), TNFα (D) and IL-1β (E) 
expression levels compared to vehicle, sham, BI-1 siRNA or Nrf-2 siRNA groups. (Data 
expressed as mean +/− SD; *p<0.05 vs sham; #p<0.05 vs vehicle; @p<0.05 vs Ad-
TMBIM6 or scramble; n=6/group using one-way ANOVA followed by Tukey multiple-
comparison post hoc analysis).   
Fluorescent staining detected significantly more positively IL-1β stained microglia in 
vehicle, BI-1 siRNA and Nrf-2 siRNA groups compared to sham or Ad-TMBIM6 treated 
groups (F).  (Green was for microglial staining, Red was for IL-1β. Merge showed the 
colocalization of IL-1β on microglia (E-F). Scale bar 50µm; n=3/group). 
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Figure 3.6 Fluorescent staining demonstrated BI-1’s ability to reduce ROS production 
and attenuate inflammation at 72h post HI 
DHE staining for ROS demonstrated that Ad-TMBIM6 reduced the amount of positively 
stained cells when compared to vehicle, BI-1 siRNA or Nrf-2 siRNA groups in the cortex 
(A). DHE staining around ventricles showed more positively stained ROS cells in vehicle 
compared to sham or Ad-TMBIM6 group (B). MPO staining for inflammation showed a 
significant reduction in positively stained MPO cells in Ad-TMBIM6 and sham groups 
compared to vehicle and siRNA groups (C). (Red was for ROS or MPO staining and Blue 
was for DAPI. Merge shows the number of positively stained cells (E-F). (For panel A 
scale bar = 50μm; For panel B scale bar = 100μm; For panel C scale bar = 25 μm; 
n=3/group). 
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To Investigate BI-1’s Effects on NPR-CYP Complex in an in vitro OGD Model 
As BI-1 has been previously reported to disrupt the NPR-CYP complex as well as 
activate Nrf-2 resulting in inhibition of ROS production and subsequent attenuation of 
inflammation, we employed an in vitro OGD model using a microglial cell line to test the 
specificity of BI-1 related attenuation of ROS induced inflammation in microglia. To test 
BI-1’s pathway, we administered a BI-1 siRNA to knockdown BI-1 expression levels and 
a Nrf-2 siRNA to silence Nrf-2 expression. Data showed that administration of Ad-
TMBIM6 vector significantly upregulated BI-1 levels in cells, both in treated and 
scramble control group, while BI-1 siRNA group reversed those effects, Nrf-2 siRNA did 
not affect BI-1’s levels (Figure 3.7A-B). Intervening at either BI-1 level or Nrf-2 level 
with siRNAs significantly reversed BI-1’s protective effects as seen from the increased 
expression levels of inflammatory markers, IL-6, TNFα and IL-1β when compared to Ad-
TMBIM6 treated group, sham or scramble groups (Figure 3.7C-E). Ad-TMBIM6 
inhibited P4502E1, the major source of ROS production, while simultaneously 
upregulating pNrf-2 levels (Figure 3.7F-G). Silencing BI-1 or Nrf-2 reversed those 
effects. Percent cell viability data showed that Ad-TMBIM6 was able to significantly 
improve the percent of viable cells while knockdown of BI-1 and Nrf-2 reversed those 
effects (Figure 3.7H). 
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Figure 3.7 BI-1 exerted its anti-inflammatory effects via inhibition of P4502E1 and 
upregulation of Nrf-2 in an in vitro OGD model 
Representative picture of western blot bands showing protein expression levels (A). 
Quantification data of bands showed that BI-1 expression levels were significantly 
increased in the Ad-TMBIM6 treatment group and in scramble control group, while BI-1 
siRNA reversed that effect (B). Ad-TMBIM6 and scramble control group significantly 
reduced IL-6 (C), TNFα (D) and IL-1β (E) expression levels. Expression levels of P4502E1 
were significantly upregulated in vehicle, BI-1 siRNA and Nrf-2 siRNA groups versus 
sham, Ad-TMBIM6 treated group or scramble control group (F). Ad-TMBIM6 and 
scramble control group significantly upregulated pNrf-2 levels which was reversed by BI-
1 siRNA and Nrf-2 siRNA (G). Cell viability data showed a significantly higher percentage 
of viable cells in Ad-TMBIM6 group and scramble control group versus vehicle, BI-1 
siRNA or Nrf-2 siRNA groups (H). (Data represent +/− SD; *p<0.05 vs control; #p<0.05 
vs vehicle; @p<0.05 vs Ad-TMBIM6 and scramble; $p<0.05 vs BI-1 siRNA; n=4-5/group 
using one-way ANOVA followed by Tukey multiple-comparison post hoc analysis).   
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Discussion 
The Endoplasmic Reticulum (ER) is a major organelle that has an essential role in 
multiple cellular processes. One of these major roles is the control of correct protein 
folding and function (Xu et al. , 2005; Zhang et al. , 2014). A wide variety of external 
factors may contribute to a disruption in ER homeostasis, such as hypoxia ischemia, 
oxidative stress, calcium disturbances and inhibition of protein glycosylation, which all 
cause ER stress (Zhang et al. , 2014). Cells may respond to ER stress in various ways, 
activating several pathways, including promoting the ability of proteins to refold 
correctly, inhibiting protein translation, increasing protein degradation, stimulating the 
transcription of genes and enabling self-repair mechanisms (Zhang et al. , 2014). All 
these processes are referred to as the unfolded protein response (UPR) which under 
prolonged activation result in cell death (Xu et al. , 2005).  
Bax Inhibitor-1 (BI-1) is an evolutionary conserved protein that resides on the 
intracellular membranes of the ER (Henke et al. , 2011).  BI-1 was first named as Bax 
Inhibitor due to its ability to suppress cell death in yeast (Xu et al. , 1998). More recently 
it is also referred to as TMBIM6 as it is part of the transmembrane Bax Inhibitor-1 
containing motif 6 family (Li et al. , 2014). Overexpression of BI-1 has been 
demonstrated to play protective role in ER stress-induced cell death, and to a lesser extent 
in other ER related stresses, such as oxidative stress and inflammation. 
ER stress is associated with the production of reactive oxygen species (ROS) 
through oxidative protein folding by the NADPH-P450 reductase (NPR), as well as the 
microsomal monooxygenase system, which is composed of cytochrome P450 (CYP) 
members such as P4502E1 (Nieto et al. , 2002; Nieto et al. , 2002; Robinson et al. , 
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2011), which triggers the UPR. Study have shown that BI-1 overexpressing cells can 
regulate UPR induction and inhibit ROS accumulation under ER stress (Kim et al. , 
2009), thus making BI-1 a possibly key regulator of ROS inhibition. Cells respond to 
ROS by activating genes to encode antioxidative stress enzymes. A key transcription 
factor activated is nuclear factor erythroid 2-related factor 2 (Nrf-2), which regulates the 
production of several cytoprotective enzymes, such as heme oxygenase-1 (HO-1). HO-1 
is a rate limiting enzyme and a potent inhibitor of ROS production (Lee et al. , 2007; Kim 
et al. , 2009). Studies show, that in BI-1 overexpressing cells, the inhibition of HO-1 
attenuated BI-1 mediated protection against ER stress (Lee et al. , 2007). However, the 
role of HO-1 in BI-1’s protective mechanism is largely unknow and debatable.  
Some studies have shown that HO-1 was unaffected in BI-1 deficient mice 
embryonic fibroblast cells (Lisbona et al. , 2009). In contrast, BI-1 overexpressed cells 
showed significant suppression of ROS production in human embryonic kidney cells 
(Kim et al. , 2012). Moreover, this was shown to be due to BI-1’s inhibitory effects on 
P4502E1 expression(Kim et al. , 2009). The P4502E1 member of the cytochrome P450 
ER heme proteins, is a major contributor to ROS production. It acts by metabolizing and 
activating substrates into more toxic products, thus not only increasing ROS production 
but also stimulating inflammatory cascades and ultimately worsening HI pathology. 
P4502E1 has been shown to be upregulated during ER stress in several studies (Lee et 
al. , 2007; Kim et al. , 2009; Kim et al. , 2012; Lee et al. , 2012), thus playing an 
important role in HI pathology.  
BI-1 may inhibit ROS accumulation by binding to NPR and disrupting the NPR-
CYP complex by decreasing electron uncoupling.  It was found that BI-1 overexpressing 
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cells caused P4502E1 degradation, leading to ER stress suppression, and subsequently 
causing ROS reduction (Lee et al. , 2012). In addition, other studies showed that 
P4502E1 induced oxidative stress played a role in translocation of Nrf-2 to the nucleus 
followed by upregulation of anti-oxidant gene HO-1. Moreover, increased HO-1 levels 
may be dependent on P4502E1 (Gong et al. , 2003), perhaps attempting to counteract 
P4502E1 effects and act as survival signal. The same study showed that inhibition of 
P4502E1 significantly reduced ROS generation in an acute kidney injury model (Wang et 
al. , 2014). The relationship between P4502E1 and HO-1 needs further research to fully 
understand the specifics covering the apparent connection. Since P4502E1 is a major 
regulator of ROS production and that Nrf-2 has a role in the response against P4502E1, 
inhibition of P4502E1 coupled with activation of Nrf-2 is a promising therapeutic target. 
Therefore, in this study we investigated the role of overexpressing BI-1, by administering 
Adenoviral-TMBIM6 vector intracerebroventricularly at 48h pre-HI, on ER stress 
induced accumulation of ROS and subsequent inflammation. We hypothesized that BI-1 
may carry this protective effect by interacting with the CYP-NPR complex while also 
upregulating Nrf-2 levels.  
Although we are now beginning to understand the importance of BI-1 in the cell 
and in human physiology, its function and signaling mechanisms remain unknown. In 
view of the importance of P4502E1 and Nrf-2, finding a key molecule to regulate both is 
of great interest. Here we identified BI-1 as one such potential molecule which may 
protect the cell against ER stress induced ROS production as well as the subsequent 
increase in inflammatory response via two possible mechanisms. First, it may interact 
with NPR, thus destabilizing the NPR-CYP complex, which directly inhibits the 
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formation of ROS by reducing the activity of P4502E1 (Kim et al. , 2009). BI-1 may 
interact though its C-terminus with NPR and to lesser extend with P4502E1 (Kim et al. , 
2009). This interaction induces destabilization of the NPR-CYP complex, thus blocking 
electron transfer and ROS production (Robinson et al. , 2011). A recent study showed that 
BI-1 was able to inhibit ER stress induced ROS production via a reduction in P4502E1 
activity and protein expression (Kim et al. , 2009). We observed similar findings from our 
western blot results; overexpression of BI-1 in the neonatal rat significantly upregulated 
BI-1 levels in the brain, while simultaneously reduced P4502E1 expression levels (Figure 
3.3A-C). Inhibition of BI-1 with BI-1 siRNA reversed those effects, while inhibition of 
Nrf-2 did not seem to significantly change P4502E1 levels, indicating its action as 
downstream. This data was further supported by our IHC staining that demonstrated 
across groups that: as BI-1 expression increased, P4502E1 decreased; they have converse 
expression patterns throughout (Figure 3.3D-E).  
Secondly, BI-1 may upregulate Nrf-2 which in turn triggers HO-1 thus inhibiting 
ROS production and attenuating inflammation. Lee et al 2007 showed that 
overexpression of BI-1 in cells increased Nrf-2 transcription factor, which then 
translocated to the nucleus where it stimulated production of anti-oxidant enzymes such 
as HO-1. HO-1 is known to block ROS production and accumulation thereby promoting 
cell survival (Lee et al. , 2007). Similar to Lee et al, we found that BI-1 overexpression, 
after neonatal HI, significantly upregulated Nrf-2 (Figure 3.4C) and HO-1 (Figure 3.4D) 
while silencing of either BI-1 or Nrf-2 with siRNAs reversed those effects. In addition, 
our IHC staining showed changes in Nrf-2 expression patters among groups which 
correlated with our western blot findings (Figure 3.4F). Furthermore, inhibition of 
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P4502E1 with activation of Nrf-2 and HO-1 was linked with reduction in ROS 
accumulation and the subsequent release of pro-inflammatory mediators. Here, we used a 
ROS marker, Reactive Oxygen Species Modulator 1 (ROMO1), which is protein coding 
gene responsible for ROS generation. There was a significant reduction in ROMO1 
expression levels (Figure 3.5A-B) as well as in IL-6, TNF-α and IL-β (Figure 3.5C-D). 
Staining for IL-1β on microglia demonstrated a significantly higher expression and 
colocalization in vehicle, BI-1 siRNA and Nrf-2 siRNA groups compared to sham or Ad-
TMBIM6 treated group (Figure 3.5F). These results were confirmed to be via BI-1 
induced inhibition of P4502E1 or activation of Nrf-2 as either inhibition of BI-1 or Nrf-2 
reversed those effects. To further examine BI-1’s inhibitory role on ROS accumulation, 
we used a Dihydroethidium (DHE) dye was used to detect ROS production. DHE is 
possibly the most specific and least problematic dye for detection of superoxide radicals 
(Owusu-Ansah et al. , 2008). Once cells are stained with DHE, the dye binds with the 
superoxide anions, thus illuminating a red fluorescent image which is an indication of 
ROS presence. Our data indicated a higher amount of ROS accumulation in vehicle, BI-1 
siRNA and Nrf-2 siRNA groups versus sham or Ad-TMBIM6 treated groups, in both 
cortex region and around ventricles, while overexpression of BI-1 showed a reduction in 
ROS (Figure 3.6A-B). To detect whether a reduction in ROS was associated with a 
reduction in inflammation we performed immunofluorescence staining for 
Myeloperoxidase (MPO). Similar pattern was observed in the MPO staining where Ad-
TMBIM6 significantly reduced MPO positively stained cells compared to vehicle, BI-1 
siRNA or Nrf-2 siRNA groups (Figure 3.6C) thus indicating a correlation between a 
reduction in ROS and the subsequent attenuation of the inflammatory processes.  
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In summary, overexpression of BI-1 with Ad-TMBIM6, promotes cell survival by 
increasing production of anti-oxidant enzymes as well as destabilizing the complex 
responsible for ROS production. This was observed as inhibition either at the BI-1 or 
Nrf-2 level; with siRNAs reversed BI-1’s protective effects by altering P4502E1, Nrf-2 
and HO-1 expressions.  This is indicative of BI-1’s ability to interact with the NPR-CYP 
complex and induce dissociation, thus disrupting the electron flow, as a physical 
association between NPR and CYP is required for production of ROS.  Furthermore, BI-1 
was shown to directly upregulate Nrf-2 thus triggering HO-1 to inhibit ROS. These two 
mechanisms play a major role in BI-1’s anti-inflammatory effects.  
To ensure the above in vivo results were also specific to microglia, we employed 
an in vitro oxygen glucose deprivation (OGD) model in an immortalized microglial cell 
line. HAPI cells were transfected with (1) BI-1 siRNA in combination with human 
adenoviral TMBIM6 (Ad-TMBIM6; gene responsible for expressing BI-1 (Bailly-Maitre 
et al. , 2010) vector to test the role of the BI-1 and NPR-CYP complex; and (2) Nrf-2 
siRNA together with Ad-TMBIM6 to test the involvement of Nrf-2 and HO-1 in BI-1’s 
effects. Cells were collected after OGD and used for cell viability and western blot 
analysis.  Cell viability data indicated that Ad-TMBIM6 significantly increased the 
percentage of viable cells when compared to cells that underwent 3h OGD without Ad-
TMBIM6 (Vehicle) (Figure 3.7). Furthermore, BI-1 siRNA or Nrf-2 siRNA significantly 
reversed Ad-TMBIM6s protective effects (Figure 3.7).  
Western Blot experiments further supported our cell viability data (Figure 3.7). 
Results indicated that Ad-TMBIM6 successfully upregulated BI-1’s expression levels in 
HAPI cells, while concomitantly reducing the pro-inflammatory markers (Figure 3.7). 
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Inhibition either with BI-1 siRNA or Nrf-2 siRNA increased the pro-inflammatory 
markers. In addition, similar trends were seen in our in vitro model for P4502E1 and Nrf-
2 levels in comparison to our in vivo model. Data showed that while BI-1 overexpressing 
cells successfully reduced P4502E1 levels while upregulating Nrf-2, either inhibiting BI-
1 or Nrf-2 reversed that trend.    
This data showed a strong support of BI-1’s ability to inhibit P4502E1 thus 
disrupting the complex while upregulating the anti-oxidant factor Nrf-2, hence 
attenuating ROS production and inflammation after HI. These data expand the current 
evidence on BI-1 as a protective protein and advance the in vitro studies done by Kim et 
al and Lee et al to a in vivo stroke model. A major challenge with any design to inhibit 
either cell death pathways or inflammatory pathways caused by ER stress lies in the 
existence of the several parallel pathways that may act at the same time. Thus, focusing 
on only one may not be ideal to preserve cell survival. Based on the evidence, BI-1’s role 
as both an anti-inflammatory mediator, and as an anti-apoptotic protein with its ability to 
influence several major ER stress related pathways, makes BI-1 an ideal and promising 
candidate for potential therapeutic approach. 
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CHAPTER FOUR 
DISCUSSION AND CONCLUSION 
The role of Bax Inhibitor-1 (BI-1) as a potential therapeutic target against 
Endoplasmic Reticulum (ER) stress and its potential effects on pathophysiological 
outcomes after hypoxic ischemic (HI) insult has not been reported previously. Several 
studies have shown BI-1’s anti-apoptotic and anti-oxidative properties (Chae et al. , 
2004; Kim et al. , 2009; Bailly-Maitre et al. , 2010), however, little is known about its 
signaling mechanism which limits its clinical translation. In this study, we showed for the 
first time that overexpressing BI-1, with gene delivery of adenoviral-TMBIM6 (Ad-
TMBIM6) vector, attenuated short and long-term deficits after HI in a neonatal rat pup. 
BI-1’s protection was mediated through IRE1α inhibition as well as through dissociation 
of the NPR-CYP complex coupled with upregulation of Nrf-2.  
We employed both an in vitro, oxygen glucose deprivation (OGD) model, and in 
vivo neonatal hypoxic ischemic model in rat pup. The main findings of our study are: (1) 
In vitro experiments using the OGD model showed that cells transfected with Ad-
TMBIM6 significantly improved cell viability, whereas silencing the TMBIM6 gene 
reversed those effects. (2) In our OGD experiments we elucidated at least one major 
pathway via which BI-1 attenuated apoptosis. Results indicated that BI-1 exerts its anti-
apoptotic effects via inhibition of IRE1α and to a lesser extend via PERK. (3) 
Administration of Ad-TMBIM6 in a neonatal rat subjected to HI, improved both short 
and long-term outcomes after HI. (4) At Least one of BI-1’s signaling pathways was 
confirmed to be via IRE1α inhibition, and its downstream molecules, thus attenuating 
apoptosis, in a rat HI model. (5) BI-1 disrupted the NPR-CYP complex, which was 
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coupled with upregulation of Nrf-2 and anti-oxidant enzymes, HO-1, and this attenuated 
ROS generation and subsequent inflammation.  
Historically, there has been a vast focus on anti-apoptotic and anti-inflammatory 
processes after hypoxic or ischemic events. Specifically, the Bcl-2 protein family has 
been extensively studied in this context, but reports have shown that most members of 
that family are poorly conserved in animals (Rojas-Rivera et al. , 2015). In contrast, the 
TMBIM family are highly conserved evolutionary proteins with common ancestors in 
yeast (Xu et al. , 1998; Rojas-Rivera et al. , 2012). One member of the TMBIM family, 
Bax Inhibitor-1 (BI-1) protein, has been well described as an anti-apoptotic protein 
conferring protection in cells and animal studies (Bailly-Maitre et al. , 2006; Lee et al. , 
2007; Kim et al. , 2009; Lisbona et al. , 2009). The BI-1 is a small, six-helix domain 
protein located primarily in the endoplasmic reticulum (ER) (Xu et al. , 1998). It was first 
identified in human screening to evaluate proteins that could inhibit Bax-mediated cell 
death (Xu et al. , 1998). It was first referred to as the testis enhanced gene transcript 
(TEGT), as it was found to be in high abundance in rat and mouse testis (Walter et al. , 
1994; Walter et al. , 1995). The gene was also detected in the brain, liver, kidney, 
thalamus, lung, ovary and heart of rat (Walter et al. , 1994).  
Since its initial discovery, BI-1’s anti-apoptotic effects have been studied 
extensively by many groups. BI-1protected yeast cells and HEK293 cells against 
overexpression of Bax (Xu et al. , 1998). It was protective in plants by inhibiting Bax and 
H2O2 (Kawai et al. , 1999). BI-1 can even attenuate Chlamydia induced apoptosis in 
HeLa cells (Perfettini et al. , 2002).  
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With more and more emerging studies it soon became evident that BI-1’s 
protection was most prominent in ER stress and ischemia-reperfusion injury. ER stress is 
a major pathology encountered due to the accumulation of misfolded proteins, after HI. A 
series of in vitro studies were employed that showed BI-1’s protection against various ER 
stress inducers like thapsigargin, and tunicamycin, which are both inhibitors of transport 
of proteins between ER and Golgi (Chae et al. , 2004). BI-1 also showed protection in 
HEK293 cells and neuronal cells after oxygen glucose deprivation (OGD) (Bailly-Maitre 
et al. , 2006). Studies then moved on to culturing cells from transgenic animals 
overexpressing BI-1, this demonstrated that cells were protected when exposed to various 
stresses (Chae et al. , 2004). In contrast, cells that were cultured from BI-1 deficient 
models were much more sensitive to ER stress or ischemia reperfusion injury (Krajewska 
et al. , 2011). Similarly, knock down of BI-1 using shRNAs also demonstrated increased 
sensitivity to ER stress in HeLa cells (Xu 2008). In recent studies of in vivo models of 
ischemia-reperfusion, traumatic brain injury or SAH, BI-1 overexpression conferred 
protection by interfering with ER stress induced apoptotic signals (Chae et al. , 2004; 
Krajewska et al. , 2011; Shi et al. , 2018).  
BI-1 has also been described in diverse other functions. BI-1 acted as a negative 
regulator of ER stress sensors, such as IRE1α (Lisbona et al. , 2009), it can increase actin 
polymerization (Lee et al. , 2010), regulate the release of calcium from intracellular 
stores (Chae et al. , 2004) and reduce reactive oxygen species (ROS) generation by direct 
interaction with members of the microsomal monooxygenase system (MMO), 
cytochrome P450 (CYP) and NADPH-P450 reductase (NPR) (Kim et al. , 2009). 
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In vitro studies described BI-1’s protective functions to be against ER stress 
inducers. Bailly- Maitre and colleagues used BI-1 knockout samples, from liver and 
kidney, to analyze ER stress markers (Bailly-Maitre et al. , 2006). The most striking 
results were the evident increase of the spliced X-box-binding protein-1 (XBP1), which is 
a downstream regulator of IRE1α. This data was later confirmed by Lisbona et al, where 
a significant increase of XBP1 was observed in BI-1 knockout animals which was 
correlated with an increase in IRE1α activity (Lisbona et al. , 2009). There was 
speculation that BI-1 may have some direct relationship with IRE1α-XBP1, since wild 
type cells that were treated with ER stress inducers, like tunicamycin, showed an initial 
increase in XBP1 which then decreased over time. However, in BI-1 knockout cells, the 
levels of XBP1 remained elevated, thus suggesting inhibitory function of BI-1 on XBP1. 
This observation was soon confirmed to be via BI-1’s inhibitory effect on IRE1α-XBP1 
by direct interaction with IRE1α protein through its C-terminus (Lisbona et al. , 2009). 
Co-immunoprecipitation experiments have shown this direct interaction between BI-1 
and IRE1α. In a cell culture study where cells were BI-1 deficient, knockdown of either 
IRE1α or XBP1 further exacerbated the damage caused by tunicamycin (Lisbona et al. , 
2009). BI-1’s role was also reported in obesity. It regulated glucose metabolism and 
reversed hyperglycemia in obese mice that were administered adenoviral-TMBIM6 
vector, which caused them to overexpress BI-1 (Bailly-Maitre et al. , 2010). This was 
hypothesized to be via the inhibition of IRE1α and attenuation of XBP1 splicing in mice 
overexpressing BI-1 in liver. This gives a strong support to BI-1’s role on ER stress 
sensors, however, more work is needed to show this intricate relationship and its effects 
in stroke.  
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Some reports have shown that BI-1 may also indirectly inhibit another ER stress 
induced protein, PERK (Lee et al. , 2007). In contrast, another study reported that BI-1 
may not have any effect on that pathway, as eIF2α phosphorylation levels, a downstream 
factor of PERK, were unchanged in BI-1 knockout mice (Bailly-Maitre et al. , 2006).    
Therefore, due to the controversies of BI-1’s role in PERK signaling, we used an 
OGD model to first establish BI-1’s role on the two branches of the UPR that are 
activated during ER stress, IRE1α and PERK. We intervened at both receptor levels to 
help us elucidate BI-1’s predominant pathway via which it attenuates ER stress induced 
apoptosis. Our data indicated that cells transfected with Ad-TMBIM6 significantly 
improved percent cell viability after 3h of OGD, while silencing BI-1 reversed those 
effects. In conjunction with above mentioned studies, we also observed an inhibition of 
IRE1α and XBP1 in cells overexpressing BI-1, while either inhibiting BI-1 or using an 
IRE1α agonist (APY-29) abrogated those effects and exacerbated the injury. This was 
seen from the increase in the pro-apoptotic marker, cleaved-caspase 3, levels. 
Furthermore, we compared BI-1’s role on the IRE1α branch to the PERK branch and 
observed that cells overexpressing BI-1, that were transfected with either a PERK 
agonist, CCT020312, or inhibition of PERK with a CRISPR k/o, did not alter BI-1’s 
expression levels. Additionally, cleaved caspase-3 levels were lower in BI-1 
overexpressing cells transfected with an IRE1α inhibitor versus that of cells transfected 
with PERK inhibitor. This is an indication that BI-1 may more potently attenuate 
apoptosis via IRE1α inhibition than via PERK inhibition. This result suggests that a 
direct interaction exists between BI-1 and IRE1α, but not between BI-1 and PERK, thus 
BI-1 has a more potent effect on IRE1α (Lee et al. , 2007; Lisbona et al. , 2009). Our data 
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also supports that interaction, as we saw intervening at IRE1α levels caused changes in 
BI-1 expression patterns whereas manipulation of PERK did not alter BI-1’s levels.  
To date, BI-1’s role and signaling mechanisms have not been elucidated in a 
neonatal HI rat model. In this study, for the first time, we showed that overexpressing BI-
1, using an Ad-TMBIM6, administered intracerebroventricularly into the neonatal brain, 
conferred protection after HI. Ad-TMBIM6 significantly reduced percent infarcted area, 
attenuated neuronal apoptosis and long-term motor, learning and memory deficits. 
Morphological analysis revealed lower percentage of tissue loss in animals 
overexpressing BI-1 versus animals in vehicle group. These protective effects were 
observed to be via inhibition of the IRE1α branch of the ER stress response signaling 
pathway.  
In conjunction with activating the UPR and initiating pro-apoptotic signaling, ER 
stress has also been linked with increased reactive oxygen species (ROS) which leads to 
oxidative stress and inflammation (Cao et al. , 2014; Zeeshan et al. , 2016). HI can 
trigger a robust inflammatory response prompting the activation of inflammatory cells in 
the brain which exacerbates brain injury (Zhao et al. , 2016). ROS is generated due to 
activation of these inflammatory cells, which further contributes to the activation of pro-
inflammatory mediators.  Apart from BI-1’s role as an anti-apoptotic protein and its 
ability to attenuate the UPR response, it has also been implicated in its ability to reduce 
ROS (Kawai-Yamada et al. , 2004; Kim et al. , 2009; Henke et al. , 2011).  
Overexpression of BI-1 reduced ROS and attenuated oxidative damage (Kim et 
al. , 2009). A major contributor to ROS generation during ER stress is from the 
microsomal monooxygenase system (MMO). This occurs as a result of electron leakage 
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between NPR and the major component of the MMO system, P4502E1 (CYP). 
Specifically, P4502E1 activity was increased in response to ER stress inducers, 
thapsigargin, while BI-1 overexpressing cells inhibited P4502E1 expression (Kim et al. , 
2009). Levels of P4502E1 were lower in BI-1 cells versus wildtype, which was consistent 
with lower levels of ROS accumulation. Although BI-1 attenuates P4502E1 expression 
and activity, a clear interaction between these two has not been shown. Instead, co-
immunoprecipitation studies have shown a physical interaction to exist between BI-1 and 
NPR (Kim et al. , 2009). It has been suggested that BI-1 may induce dissociation of the 
NPR-CYP complex by directly binding to NPR and reducing the electron transfer 
between these two and hence reducing ROS (Kim et al. , 2009). A second possible 
mechanism of BI-1 protection against ROS is via upregulation of anti-oxidant factors, 
such as Nrf-2 and HO-1. Cells overexpressing BI-1 have higher levels of Nrf-2 and HO-
1, which was linked to a reduction in ROS (Lee et al. , 2007).  
To examine this possibility after neonatal HI injury, we tested this pathway in a 
rat subjected to unilateral carotid artery ligation, followed by hypoxia to induce HI injury. 
We used siRNAs to silence BI-1 or Nrf-2 and detected that silencing of BI-1 increased 
P4502E1 expression levels, which was correlated with an increase in ROS and 
inflammatory mediators. In addition, silencing of Nrf-2 showed similar results. 
Furthermore, rats that were administered Ad-TMBIM6 without siRNAs had significantly 
reduced P4502E1 expression levels together with upregulation of Nrf-2 and HO-1 with 
subsequent attenuation of ROS and inflammation. Here we showed that BI-1 can also 
attenuate oxidative stress and inflammation via increased production of anti-oxidant 
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enzymes coupled with destabilization of the NPR-CYP complex in a neonatal HI rat 
model.   
Understanding BI-1’s signaling mechanisms pertaining to inhibition of ER stress 
induced injury after HIE is crucial in establishing how the two components interrelate.   
 
Clinical Significance 
Given the limited therapeutic options for hypoxic ischemic encephalopathy (HIE) 
it is necessary to understand cellular and molecular mechanisms which can lead to more 
effective therapeutic strategies. Hypothermia is the only therapy that has shown success 
(Meloni 2008), but despite that, a large percentage of neonates still develop long-term 
complications.   
The lack of adequate mechanistic animal studies, therapeutic window, timing of 
treatment and various other factors halt the progression of promising targets to be 
translated to clinics.  
 
Can BI-1 Be a Potential Therapeutic Target? 
One must consider the plethora of signaling mechanisms that can be 
activated/inhibited by BI-1. It can regulate calcium release, bind to and activate Bcl-2 and 
inhibit Bax, attenuate UPR proteins activated as a result of ER stress, reduce production 
of ROS and increase actin polymerization (Kim et al. , 2008; Henke et al. , 2011). BI-1’s 
multimodal properties suggest that it can target a wide array of pathophysiological 
consequences after HIE. Therefore, this makes BI-1 a potential therapeutic target and 
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may change the clinical management for patients with HI injury and provide a foundation 
for future research in other types of strokes with similar pathologies 
The only caveat is that there is a lack of in vivo studies showing BI-1’s diverse 
roles. A vast majority of the studies have been done in cell culture models. Therefore, it 
is imperative to translate those in vitro studies to in vivo disease models. Additionally, 
BI-1’s anti-apoptotic roles might be detrimental in some disease processes such as in an 
infection. For example, BI-1 may act in conjunction with pathogens to promote cell 
survival of infected cells (Robinson et al. , 2011). Some pathogens contain molecules that 
can bind with BI-1 and inhibit apoptosis, therefore, promoting survival of the infected 
cell. One such molecule was found to be NIeH, that bound to BI-1 and decrease calcium 
release during infection, thus blocking apoptosis (Hemrajani et al. , 2010). It is crucial to 
determine all of BI-1’s functions and signaling mechanisms in a wide array of disease 
models before it can be translated to clinical studies.  
 
Conclusion 
There has been considerable progress made in understanding BI-1 and its role in 
apoptosis and disease. Despite that, the way in which it functions in stroke and other 
disease models remains to be elucidated. We showed that overexpressing BI-1 in a 
neonatal rat brain conferred protection after HI injury by reducing apoptosis and 
oxidative stress. Agonizing the effects of ER stress with silencing either BI-1 or the anti-
oxidant transcription factor Nrf-2, or further upregulating IRE1α signaling, exacerbated 
the injury even with Ad-TMBIM6 vector administration.  
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With this study we identified a novel role for BI-1 protein and endoplasmic 
reticulum stress in the pathophysiology of neonatal HI injury. We found that BI-1 
conferred an inhibitory effect on IRE1α signaling thus attenuating apoptosis. 
Additionally, we showed that BI-1 inhibited P4502E1, major component for ROS 
production, coupled with upregulation of anti-oxidant factors, Nrf-2 and HO-1, to 
attenuate oxidative stress and inflammation after HI. Nonetheless, future studies are 
needed to better understand BI-1’s role in ER stress which may aid in better 
understanding how cells can overcome stresses. In summary there are still many aspects 
to be answered about BI-1 and how it can regulate life and death. 
 
Future Directions 
In our study we focused on two general concepts: The effects of overexpressing 
BI-1 in the neonatal rat brain using gene delivery of adenoviral-TMBIM6 vector, and the 
mechanisms by which it confers its protective effects. Due to limited knowledge on BI-1 
and thereafter serious lack of specific drugs targeting it, we used an adenoviral vector to 
over express the TMBIM6 gene, which can overexpress BI-1 protein. However, using 
adenoviral vectors takes multiple days to begin expressing, causing a delay in treatment 
and possibly missing the optimal therapeutic window. Further exploration and 
development of more adequate ways to target BI-1 overexpression in vivo are needed. 
Additionally, we injected the virus intracerebroventricularly, future research into more 
clinically translatable routs is necessary.  
Our study focused on BI-1’s role in ER stress after neonatal HIE, however, there 
are many other areas yet to be investigated in various other stroke models and diseases. 
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The protection conferred after HIE in this study via inhibition of IRE1α and dissociation 
of the NPR-CYP complex may not be optimal in other models of disease. Further research 
is necessary to see BI-1’s role in diseases and potential alternative pathways that may be 
involved. There is a possibility that BI-1’s effects extend beyond the ER stress mechanisms 
and these need to be evaluated in subsequent studies. 
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